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The prevalence of obesity has continued to rise over the last several decades in the
United States lending to overall increases in risk for chronic diseases including many types
of cancer. In contrast, reduction in energy consumption via calorie restriction (CR) has been
shown to be a potent inhibitor of carcinogenesis across a broad range of species and tumor
types. Previous data has demonstrated differential signaling through Akt and mTOR via the
IGF-1R and other growth factor receptors across the diet-induced obesity (DIO)/CR
spectrum. Furthermore, mTORC1 is known to be regulated directly via nutrient availability,
supporting its role in the link between epithelial carcinogenesis and diet-induced obesity. In
an effort to better understand the importance of mTORC1 in the context of both positive and
negative energy balance during epithelial carcinogenesis, the use of specific
pharmacological inhibitors, rapamycin (mTORC1 inhibitor) and metformin (AMPK activator)
was employed to target mTORC1 or various components of this pathway during skin tumor
promotion. Two-stage skin carcinogenesis studies demonstrated that mTORC1 inhibition
via rapamycin, metformin or combination treatments greatly inhibited skin tumor
development in normal, overweight and obese mice. Furthermore, mechanisms by which
these chemopreventive agents may be exerting their anti-tumor effects were explored. In
addition, the effect of these compounds on the epidermal proliferative response was
analyzed and drastic decreases in epidermal hyperproliferation and hyperplasia were
found. Rapamycin also inhibited dermal inflammatory cell infiltration in a dose-dependent
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manner. Both compounds also blocked or attenuated TPA-induced signaling through
epidermal mTORC1 as well as several downstream targets. In addition, inhibition of this
pathway by metformin appeared to be, at least in part, dependent on AMPK activation in
the skin.
Overall, the data indicate that pharmacological strategies targeting this pathway
offset the tumor-enhancing effects of DIO and may serve as possible CR mimetics. They
suggest that mTORC1 contributes significantly to the process of skin tumor promotion,
specifically during dietary energy balance effects. Exploiting the mechanistic information
underlying dietary energy balance responsive pathways will help translate decades of
research into effective strategies for prevention of epithelial carcinogenesis.
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Chapter 1: Introduction and Background
1.1

Dietary energy balance and cancer

Dietary energy balance refers to the relationship between calories consumed and calories
expended. A positive state of energy balance occurs when the ratio of calories consumed is
higher than those expended, and a negative state of energy balance occurs when more
calories are expended than consumed. A chronic state of positive energy balance leads to
overweight and obesity and is associated with “metabolic syndrome” or a cascade of
metabolic disorders leading to the development of cardiovascular disease, type II diabetes
as well as many types of human cancer. Estimates from the Cancer Prevention Study II,
suggest that 14% of all cancer deaths in men, and 20% of all cancer deaths in women can
be attributed to excess body weight, and this is relevant for a range of cancer types (1).
Obesity has risen drastically over the past several decades in the United States and,
according to 2010 estimates from the Centers for Disease Control and Prevention, more
than one third (35.7%) of US adults and a startling 17% of children and adolescents are
obese (2). In addition, many animal models also support this association between obesity
and cancer. Chronic consumption of an ad libitum high fat diet, in which 45-60% of Kcal are
from fat, leads to diet-induced obesity (DIO) and is associated with many chronic diseases
including type II diabetes and many types of cancer in rodents, some of which include
pancreas, breast, colon, liver, ovarian and lung (3-6). In addition, two-stage murine skin
carcinogenesis model studies have also demonstrated a role for a high-fat diet in
accelerating the rate of tumor development during epithelial carcinogenesis, and when the
high fat diet was administered in an isocaloric manner, (diet high in corn-oil but isocaloric)
papilloma multiplicity and incidence in SENCAR mice were significantly increased (7).
However, these studies did not specifically evaluate the effects of DIO (weight gain and
adiposity) on susceptibility to tumorigenesis, and effects and mechanisms underlying
positive energy balance are thus less well studied.
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On the opposite spectrum, negative energy balance, achieved by calorie restriction
(CR) has been shown to universally inhibit carcinogenesis and other chronic diseases
across species, as well as extend lifespan (8). CR is an experimental mode in which total
energy intake is restricted. Typically, test subjects receive a 15-40% reduction in calories
(fat and/or carbohydrates) as compared to an ad libitum control fed group but still maintain
isonutrient conditions (9). Consistently, CR has been shown to be a potent inhibitor of
carcinogenesis in animal models and acts broadly with respect to type of tumor affected as
well as mode of induction.

1.2

Mechanisms of energy balance effects on carcinogenesis

CR is considered to be one of the most potent dietary manipulations used to suppress the
carcinogenic process, and many key studies in animal models have supported this notion.
With more and more of the US population’s accession to obesity, it is becoming ever more
important to translate knowledge from animal models into human chemoprevention
strategies. In order to achieve this, understanding the underlying mechanisms responsible
for the differential effects of CR and DIO on tumorigenesis is critical. Current studies have
shown that these effects are multifaceted and thus are achieved through the combined
effects of numerous cellular and biochemical processes, some of which affect hormones
and growth factor signaling as well as inflammation.

Globally Active Circulating Proteins
It is thought that a primary mechanism of action responsible for dietary energy
balance effects on tumorigenesis is through variations in serum-related hormones and
growth factors that regulate many physiological processes. Some of these include but are
not limited to appetite, energy expenditure and metabolism, and thermoregulation. Recent
evidence from the literature suggests that primary mediators include insulin, insulin-like
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growth factor-1(IGF-1), and glucocorticoids as well as the adipokines, leptin and
adiponectin (Figure 1-1) (10).
CR has been shown to reduce circulating insulin levels, while obesity increases
them. During conditions of chronic hyperinsulinemia and insulin resistance in particular,
insulin has been shown to increase cancer risk at several organ sites (11). Additionally, it is
unclear if increases in tumorigenesis can be primarily attributed to the direct effects of
insulin receptor activation and subsequent downstream signaling, or if indirect effects on
IGF-1 synthesis or other hormones are primarily responsible. Circulating levels of IGF-1 are
determined by hepatic synthesis which is regulated by variations in overall insulin and
growth factor levels due to variations in energy and nutrient intake. High circulating levels of
insulin also decrease the availability of IGF binding protein-1, subsequently providing more
bioavailable IGF-1. There is also recent evidence of crosstalk between the insulin receptor
and many hormonal pathways thus further complicating its role in energy balance effects
(12, 13).
Consistently, in vitro studies have provided evidence that IGF-1 enhances cellular
growth in a variety of cancer cell lines (14). In addition, it has been identified as a cell cycle
progression factor through its activation of the phosphoinositide-3-kinase (PI3K)/Akt signal
transduction pathway and subsequent stimulation of G1 to S phase progression (15, 16).
This is also supported in vivo as studies using LID (reduced circulating IGF-1) mice showed
reductions in tumor burden in both an orthotopic model of pancreatic cancer (17) as well as
in a two-stage chemical skin carcinogenesis model (18). It is important to note that in each
of these studies, while there was a 75% reduction in circulating IGF-1, insulin levels
remained high, thus making it hard to discern the primary mediator of energy balance
effects.
Adipokines, which are cytokines secreted from adipocytes, have also been identified
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as mediators in energy balance effects. Leptin, a 16 kDa adipocyte derived cytokine
regulates metabolism and satiety by acting in the hypothalamus to send a cascade of
neuroendocrine signals (19). Leptin is differentially regulated by DIO and CR, and levels
strongly correlate to overall body weight and fat mass. In normal weight individuals,
increases in leptin result in decreased appetite while an obese state has consistently been
shown to increase overall circulating levels of leptin to a point of causing leptin resistance
(20-22). It is thought that this resistance causes the exogenous leptin to lose its ability to
prevent weight gain (22). In addition, this rise in circulating leptin is associated with
increased cancer risk for many types of cancer most notably colorectal and prostate cancer
with limited data supporting a role for leptin in breast and endometrial cancers (23-25). In
vivo studies have shown that leptin may increase tumor invasion and support angiogenesis
(26), and in vitro studies have shown leptin to increase proliferation of neoplastic but not
“normal” cells (27). Leptin is a product derived from the Ob gene, and its major actions are
mediated primarily through the transmembrane leptin receptor (ObR) whereby the Janus
Kinase 2/signal transducer and activator of transcription 3 (Jak-STAT) signaling cascade is
subsequently activated. These pathways have been shown to be critical signaling pathways
during tumor development (19, 28). There is also further evidence that the importance of
leptin during energy balance modulation and cancer development could also be due to the
ratio of leptin to adiponectin in contrast to the independent effect of leptin as they act in
opposition of one another to influence carcinogenesis (29, 30). Adiponectin is a 28 kDa
adipokine insulin sensitizer that plays a key role in glucose and lipid metabolism.
Concentrations of adiponectin increase as overall weight declines and decrease in obese
and diabetic states as well as other conditions classified as “metabolic syndrome”(31).
Metabolic syndrome is the name given to a set of risk factors which include insulin
resistance, hyperglycemia, excess body weight around the waist, high blood pressure, high
triglycerides, and low HDL cholesterol levels that collectively lead to increased heart
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disease, type II diabetes and stroke. Extreme weight loss through CR and surgery has been
shown to reverse these effects (10). Although the role of adiponectin in cancer is not well
characterized, recent data suggest that levels of adiponectin may inversely correlate with
cancer development (27, 29, 32, 33). Possible mechanisms include adiponectin mediated
activation of AMP-activated protein kinase (AMPK) and subsequent inhibition of mTORC1
signaling as well as its attenuation of Stat signaling (10).
Previous CR studies have also suggested a possible role for adrenal glucocorticoids
in mediating some of the anti-cancer effects of CR. Marked increases in corticosterone
have been observed in rodents undergoing CR > 30%, and this increase was associated
with a decrease in tumor development in the two-stage skin carcinogenesis model (34).
There are several proposed mechanisms by which corticosterone may be exerting antitumor effects which include reductions in inflammation, inhibition of cell cycle progression
via p27 activation and inhibition of PKC and subsequent ERK signaling (34, 35).
Adrenalectomy studies further complicate the role of corticosterone during CR, as removal
of the adrenal gland abolished the anti-cancer effects of CR during skin tumor promotion in
mice; in contrast, adrenalectomy had no impact on CR mediated tumor growth inhibition in
rats in a chemically induced model of mammary carcinogenesis (35, 36). Additionally,
studies in a rat mammary carcinogenesis model also showed that supplementation of
corticosterone in a non-CR state inhibits tumorigenesis, but also results in dose-dependent
reductions in circulating IGF-1 levels (37).
Chronic inflammation is associated with cancer development, and more recently,
obesity (38). Increases in white adipose tissue (WAT) cause increased flux in the number of
circulating inflammatory cytokines as well as at the local or tissue level, some of which
include interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), monocyte chemoattractant
(MCP-1) as well as C-reactive protein (39). A cascade of events then occurs, beginning
with increased macrophage infiltration and further adipose-derived increases in
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inflammatory cytokines. This is followed by increased signaling through inflammatory
pathways such as NF-ҡB, STAT3, and JNK leading to a low-grade but chronic inflammatory
state giving rise to a tumorigenic environment (40).

Figure 1-1

Figure 1-1 Differential effect of DIO and CR on globally active circulating proteins
DIO or positive energy balance increases circulating levels of leptin, IGF-1, TNF-α and IL-6
and decreases levels of adiponectin. The opposite effect is seen with CR or negative
energy balance and increases in corticosterone and adiponectin occur. Changes in
circulating levels of these serum hormones and cytokines affect activation of corresponding
receptors leading to differential effects on cellular growth, proliferation and survival.
Reprinted by permission from Wiley and Sons: [Annals of the New York Academy of
Science] (10), copyright 2011
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There is also recent evidence to suggest that differential signaling through the
PI3K/Akt/mTOR pathway across the DIO/CR spectrum may provide a potential mechanism
by which dietary energy balance modulates tumorigenesis (Figure 1-2). An ad libitum diet or
consumption of a high fat diet inhibits the TSC complex, and subsequently activates
mTORC1 enabling an increase in cellular growth and proliferation. Recent data suggest
that this occurs through increases in ATP, glucose and amino acids caused by high energy
conditions. In contrast, nutrient deprivation via CR has been shown to inhibit mTORC1. It is
thought that one mechanism through which this may occur is through the LKB1/AMPK
pathway. When ATP/AMP ratios become low, AMPK is activated and phosphorylated by
LKB1 and subsequently mTORC1 is inhibited. In addition, this activation reduces energy
expenditure by the cell thus limiting stress inspired apoptosis (41). It should be noted
however that this mechanism appears to be tissue specific as CR was found to activate
AMPK in liver, skeletal muscle, and fat tissue but did not appear to be differentially
activated by DIO or CR in skin epidermis or dorsolateral prostate (42, 43). Recent studies
have also shown CR to reduce IGF-1R activation and subsequently downstream activity
(Akt, mTORC1 and downstream substrates) in a variety of epithelial tissues including skin
epidermis, liver and prostate while DIO increased activation in both steady-state conditions
as well as after TPA treatment (43). Furthermore in this study, dietary energy balance
modulation was also found to differentially modulate epidermal growth factor receptor
(EGFR) contributing to the observed differences in Akt and mTORC1 status with DIO and
CR. Another study found similar decreases in serum IGF-1 levels and decreased protein
activation of mTOR and p70S6K in mammary tumors and mammary fat pads using MMTVTGF-α mice undergoing intermittent calorie restriction (ICR) (44). Studies in LID mice also
show reductions in TPA-induced epidermal activation of Akt and mTORC1 comparable to
those undergoing CR thus further supporting the role of IGF-1 in mediating dietary energy
balance effects (18).
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Figure 1-2

Figure 1-2 Summary of dietary energy balance manipulation on epithelial growth
factor signaling. Illustration representing the proposed mechanism by which dietary
energy balance (calorie restriction and diet-induced obesity) modulates susceptibility to skin
tumor promotion. DIO increases while CR decreases circulating levels of IGF-1 which in
turn differentially regulate activation of IGF-1R and subsequently EGFR due to potential
receptor crosstalk. Akt, mTOR and other downstream targets including cell cycle regulatory
proteins such as cyclin D1, cyclin E and cyclin A are differential regulated. Dotted lines
represent potential changes supported by preliminary data. Black arrows represent
changes in epidermal signaling in obese mice, and white arrows indicate changes seen in
epidermis of CR mice.
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Additional studies have used A-ZIP/F-1 mice, which lack WAT and display low
levels of adipokines but are still insulin resistant and diabetic to enable a distinction to be
made from the effects of adiposity (leptin, adiponectin, etc.) and various hormonal factors
and signaling pathways that have been linked to obesity and tumorigenesis. These mice
were found to remain highly susceptible to tumor development in both the two-stage skin
carcinogenesis model as well as in the C3(1)/T-Ag transgenic mouse mammary model in
the absence of obesity thus further supporting the hypothesis that insulin, IGF-1 and
downstream signaling pathways as well as inflammation are the primary mediators in the
link between obesity and cancer (45).

1.3 PI3K/Akt/mTOR signaling pathway
It is well established that the PI3K/Akt/mTOR signaling pathway is a major element of IGF-1
and insulin responses that are involved in cellular metabolism and growth and that this
pathway may be a major contributor to IGF-1’s effects on tumorigenesis (15, 46, 47).
Evidence from the literature also suggests that this pathway is one of the most commonly
altered pathways found in human tumors (48, 49). Akt has been shown to regulate cell
cycle progression and cell survival via phosphorylation of many downstream effectors
including Bad, Foxo1, and GSK3β and thus mediates or promotes cellular transformation
when signaling is aberrant. IGF-1 and/or insulin bind to the IGF-1R and IR respectively and
in turn, these activated receptor tyrosine kinases and Ras, activate PI3K via scaffolding
adaptors such as insulin receptor substrate I (IRS-1) or through direct phosphorylation (11). PI3K produces phosphatidyl-inositol-3,4,5-triphosphate (PIP3) which is then bound to
Akt and PDK1, with Akt representing its primary substrate. PDK1 phosphorylates Akt at
T308 which is the activation loop (50).
Elevated levels of Akt activation have also been associated with increases in
mammalian target of rapamycin (mTOR) activity. mTOR is a highly conversed
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serine/threonine protein kinase that integrates energy sensing and nutrient status to growth
factor signaling in order to regulate multiple critical cellular processes including cellular
growth and proliferation, protein translation and autophagy (51). mTOR is composed of twodistinct complexes, mTORC1 and mTORC2. mTORC1 is composed of mLST8 and raptor
and is primarily driven by nutrient status (Figure 1-3). mTORC1 is known to be rapamycin
sensitive. External signals such as growth factor signaling via nutrient status and availability
regulate activation or repression of tuberous sclerosis complex (TSC) which is the primary
regulator of mTORC1 activation. TSC binds to and relieves G-protein Rheb from mTORC1,
subsequently inhibiting mTORC1. However, when TSC is phosphorylated it is inactivated,
and the released Rheb, in a GTP-bound state can then activate mTORC1. In addition,
PRAS40, a proline-rich Akt substrate and binding partner of raptor is a negative regulator of
mTORC1 that is released in response to insulin (52).
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Figure 1-3

Figure 1-3 Mammalian Target of Rapamycin (mTOR) signaling schematic. Illustration
representing key regulators of the mTOR signaling pathway. mTOR is a 289 kD protein
composed of two functionally distinct complexes: mTORC1 and mTORC2. Growth factors
including insulin and IGF-1 and environmental stressors such as hypoxia and energy
promote mTORC1 mediated cellular growth and proliferation through downstream targets
S6K1 and 4E-BP1 and inhibit the induction of autophagy. mTORC1 is the rapamycinsensitive complex. mTORC2 is rapamycin insensitive and activated via RTKs by an
unknown mechanism. The mTORC1/S6K1 negative feedback loop suppresses activation of
mTORC2/Akt. [Reprinted from (53) under the Creative Commons Attribution Noncommercial License]
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Primary processes of mTORC1 are carried out by downstream targets, ribosomal
S6 kinases (S6Ks, p70S6K) and 4E-binding protein-1 (4E-BP1) which are translational
regulators (54). The S6Ks have been shown to increase ribosome biogenesis and lead to
increased cellular growth although complete understandings of the mechanisms of action
behind this remain unclear. Of particular interest is S6K’s negative regulation of insulin
signaling through phosphorylation of IRS-1 and subsequent decreases in signaling through
Akt/mTOR. Because this signaling pathway is stimulated by nutrients, this negative
feedback loop may play a role in obesity related diseases (52). Further downstream of S6K,
this will be referred to hence forth as p70S6K, is Programmed Cell Death Receptor 4
(PDCD4). Emerging evidence suggests that transcription as well as translation is greatly
influenced by levels of PDCD4 which in turn modulate signaling pathways thus potentiating
PDCD4’s role as a tumor suppressor (55). During skin tumor promotion, a recent study
found tumor promoter TPA to stimulate proteasomal degradation of PDCD4 in mouse
epidermis and skin tumors, and levels inversely correlated with tumor response. Both Akt
and p70S6K were found to phosphorylate PDCD4 and target it for ubiquitylation via E3ubiquitin ligase (56). mTORC1 also regulates protein synthesis via the 4E-BPs. The 4E-BPs
inhibit protein synthesis by binding to eIF4E to prevent it from interacting with
eIF4G1/eIF4G2 and thus inhibit its function in mRNA translation, though it’s thought that
these translational repressors only affect certain mRNAs (52).
Additional downstream targets of mTORC1 include many autophagy-related genes
(ATGs). Macroautophagy is an important component of the cellular stress response,
designed to maintain cellular homeostasis. It is a catabolic process that involves the
breakdown of a large variety of cellular material and debris via delivery of these cytoplasmic
proteins and organelles by specific membranous vesicles known as autophagosomes to
lysosomes (57). The process is crucial to maintaining cellular homeostasis by eliminating
damaged proteins and organelles, as well as playing a key role in many other physiological
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processes including immunity, cellular apoptosis, and metabolism (58, 59). Deregulation of
this process has been linked to increases in susceptibility to a variety of diseases including
cancer (59, 60). Many alterations have been found in autophagic signaling pathways during
various stages of tumorigenesis. However, it is important to note that autophagy’s role in
cancer is an environment-dependent process. Autophagy maintains cellular homeostasis
which can limit the availability of a microenvironment that promotes tumor growth.
Particularly, if irregularities are present that decrease autophagic processing such as
various disease states, this may give rise to a microenvironment that is able to promote
tumorigenesis (58). In contrast, established solid tumors may actually exploit autophagy to
stimulate tumor growth and promote metastases (59).
Most pro-autophagic events including initiation and nucleation converge on the
mammalian Target of Rapamycin (mTOR) which as aforementioned serves as a critical
sensor of energy and nutrient status and a subsequent regulator of protein synthesis.
Nutrient rich states cause a complex formation between mTORC1, ULK1/2, FIP200 and
mAtg13 due to interactions between raptor and ULK1 (61). ULK1 and ULK2 are mammalian
homologs of the yeast autophagy related gene 1 (Atg1) serine/threonine protein kinase
critical for autophagic regulation (62). Phosphorylation of ULK1 and Atg13 by mTORC1
prevents the pro-autophagic kinase activity of these proteins (58).This is accompanied by
an mTORC1 mediated increase in protein synthesis. Nutrient starvation or treatment with
mTOR inhibitors reverses this negative regulation of autophagy and allows for the ULK
complex to localize to the newly forming phagophore (58, 62) (Figure 1-4).
mTORC2 associates with rictor, mLST8 and SIN1 and is activated by RTKs that
respond to stimuli that have yet to be elucidated and overall understanding of its functions
are greatly limited (15, 51). It is thought to be rapamycin-insensitive, and it primarily targets
Akt for phosphorylation at serine 473 (51). Finding specific inhibitors of mTORC2 kinase
activity will aid greatly in the understanding of control and cellular function of mTORC2.
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Figure 1-4

Figure 1-4 Schematic of mTOR/AMPK mediated regulation of ULK1 in response to
nutrient availability. Under glucose rich conditions, AMPK is inactivated and mTOR is
activated. Activated mTORC1 phosphorylates ULK1 on Serine 757 disturbing its interaction
with AMPK and subsequent activation. When nutrient availability is limited, AMPK remains
activated and thus phosphorylates TSC and inactivates mTORC1. Subsequently, AMPK
can phosphorylate ULK1 on Serine 317 and Serine 777 thereby initiating autophagy
through its activation. Reprinted by permission from Macmillan Publishers Ltd: [Nature Cell
Biology] (63), copyright 2011
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1.4

Calorie restriction mimetics: Targeting mTORC1

A new chemopreventive approach may lie in the identification or development of natural or
synthetic agents to appropriately “mimic” the protective effects generated by CR as
previous findings regarding CR and anti-cancer properties are vast. Drastic lifestyle
changes which include long-term CR are difficult for the general population to maintain. As
discussed earlier, much data supports the hypothesis that the IGF-1R and Akt/mTOR
pathways are important mediators in CR effects during tumorigenesis thus making them
front line targets for mimetic drug development. Current drugs under development have
targeted IGF-1 with small-molecule inhibitors (64) as well as with anti-sense inhibitor
approaches (65) and anti-IGF-1 antibodies (66). In addition retinoids and flavonoids which
are widely used as chemopreventive agents have also demonstrated inhibition of the IGF-1
pathway (67-69). More recent studies have begun to explore further downstream of IGF-1
with Akt and mTOR inhibitors as potential CR mimetics. As previously discussed, mTOR, a
target of Akt, has been shown to be a key component in mediating some of the effects of
aberrant Akt signaling that occur during tumorigenesis (70, 71).

1.4.1

Rapamycin

Rapamycin is a macrolide found in the soil originating as a product from the bacterium
Streptomyces hygroscopicus. Rapamycin is a powerful immunosuppressant, and it is
primarily used to prevent organ transplant rejection, especially in kidney transplant patients.
However, its anti-proliferative properties have also generated a large amount of interest in
rapamycin as an anti-cancer or chemopreventive agent. Additionally, rapamycin has been
shown to extend lifespan in mice thus exerting similar effects to CR (72). Importantly,
rapamycin is a well-established mTORC1 inhibitor. It has been shown to exert this effect by
binding to its intracellular receptor, immunophilin FKBP12, forming an inhibitory complex.
This is turn, destabilizes mTORC1 by binding to a C-terminus region on mTOR thus
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preventing mTOR interaction with raptor (73-75). mTORC2 is thought to be “rapamycininsensitive” as acute treatment has shown no effect on mTORC2 substrates, however
chronic treatment in vitro did demonstrate possible mTORC2 inhibition via decreases in
AKT/PKB which is a primary downstream target of mTORC2 (76).
Rapamycin has been shown to suppress tumorigenesis in a variety of tumor model
systems. It was found to inhibit growth of mammary lesions, both pre-malignant and
malignant transplanted from Tg (MMTV-PYV-mT) mice (77). In addition, in a xenograft
model of highly metastatic human hepatocellular carcinoma, rapamycin was found to inhibit
primary tumor growth as well as metastasis (78). Rapamycin, administered in the diet also
inhibited tumor growth in primary skin tumors induced by chronic exposure to UV (79) as
well as induced regression of late-stage skin tumors in the chemically-induced two-stage
model of skin carcinogenesis in mice (80). Chemopreventive properties of rapamycin were
demonstrated in A/J mice with carcinogen induced lung cancer as these mice displayed
marked decreases in tumor size and multiplicity (81, 82). Furthermore, several transgenic
mouse models including a head and neck SCC mouse model based on a K-rasG12D and p53
loss in the oral epithelium (83) as well as an erbB2-dependent breast cancer mouse model
(84) have demonstrated rapamycin’s potent anti-cancer properties through decreases in
tumor growth, angiogenesis and survival.

1.4.2

Metformin

Metformin is a biguanide derived from guanidine, the active ingredient in Galega officinalis
(goat’s rue). It is the most commonly prescribed oral hypoglycemic agent today with over
120 million users worldwide (85). Its primary use is in the treatment of diabetes mellitus
type 2 whereby it inhibits hepatic glucose production and induces an overall reduction in
insulin resistance. This also stimulates glucose uptake in peripheral tissues thereby
reducing overall circulating blood glucose levels. Primary mediators in these insulin and
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glucose lowering effects include AMPK activation via activation of liver-kinase B1 (LKB1).
This activation occurs through metformin’s primary mechanism of action whereby it
interferes with respiratory complex I in the mitochondria reducing overall adenosine
triphosphate levels (ATP) (86). AMPK is a central energy and nutrient sensor that responds
to variations in the ratio of AMP to ATP. Nutrient deprivation leads to activation of AMPK
and subsequent inhibition of energy consumption and related processes such as protein
translation regulated via mTOR and its various downstream targets, and fatty acid synthesis
via acetyl CoA Carboxylase (ACC) and fatty acid synthase (FASN) (Figure 1-5). Activation
of AMPK helps partially reverse the metabolic deregulation present in type II diabetes.
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Figure 1-5

Figure 1-5 Schematic of LKB1/AMPK signaling. Various downstream effectors mediate
LKB1/AMPK’s regulation of cellular growth and metabolism. Metabolic stress induces
increases in cellular AMP thus forming the AMPKα complex which can then be activated by
LKB1. The AMPK complex can also be phosphorylated by calcium/calmodulin-dependent
protein kinase (CaMKK). PP2A and PP2C inhibit its phosphorylation. Activation of AMPK
causes translocation of GLUT4 to the plasma membrane whereby it stimulates glucose
uptake and regulates downstream signaling involved in cellular gene transcription and
cellular metabolism. Reprinted by permission from Macmillan Publishers Ltd: [Oncogene]
(87), copyright 2011
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There is increasing evidence from case-control and prospective cohort studies that
type II diabetes is associated with increased cancer risk; however, there remains large
overlap in cause since there are various other cancer risk factors associated with type II
diabetes such as obesity, sedentary lifestyle, and a high-fat diet (88). With the elucidation of
AMPK’s role in metabolism, as well as all the metabolic abnormalities linked with increased
cancer risk, there is great interest in pursuing metformin as an anti-cancer/chemopreventive
agent. Population-based studies have provided evidence that patients with type II diabetes
treated with metformin have reduced cancer incidence as well as reduced mortality than
patients receiving other types of diabetes treatment (89, 90). In addition, this appears to be
true for a variety of solid tumor types. Recent epidemiological studies show a reduced
incidence of colorectal cancer in diabetic patients receiving metformin (91). Patients taking
metformin with pancreatic cancer and colorectal cancer displayed a 30% improvement in
overall survival (91, 92). A retrospective study showed that breast cancer patients taking
metformin in addition to systemic therapy, displayed an increase in the overall effectiveness
of the chemotherapy (93).
In addition, the possible anti-tumorigenic properties of metformin have been
supported in a variety of in vitro and in vivo experimental systems. Several studies in
cancer cell lines have provided evidence that metformin inhibits neoplastic growth (94, 95).
In A/J mice exposed to a tobacco carcinogen 4- (methylnitrosamino)-1-(3-pyridyl)-1butanone (NNK), both oral and intraperitoneal administration of metformin reduced lung
tumor burden. With oral administration there were modest decreases in mTOR activity in
lung tumor tissue, however upon IP injection, signaling through the IGF-1R/IR was
decreased as well as mTOR, Akt and ERK, in an AMPK independent fashion (96). In HER2/neu mice, metformin treatment via the drinking water (100 mg/kg bw per day) reduced the
size and incidence of mammary adenocarcinomas as well as prolonged lifespan (97).
Metformin administered in a basal powdered diet form (250 mg/kg bw per day) in APCmin/+
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mice was shown to reduce polyp growth as well as activate AMPK and reduce signaling
through mTOR in tumor tissue (98). Since most epidemiological studies have been
obtained from type II diabetic populations which present metabolic disorders including
obesity, hyperglycemia and hyperinsulinemia, a few studies have explored metformin’s
effect in mice receiving a high-energy vs. normal control diet on tumor growth. One study
found that oral administration via the drinking water (50 mg/kg bw per day) blocked the
stimulatory effect of a high-energy diet on growth of an in vivo model of colon carcinomas
using MC38 carcinoma cells. Metformin attenuated high-energy associated effects on tumor
growth including a reduction in insulin levels, a reduction in Akt activation in the tumor
tissue, and a reduction in expression of Fatty Acid Synthase (FASN) in tumor tissue (99).
This same group also showed that in a lewis lung LLC1 carcinoma cancer model in
C57BL/6J mice, the effect of a high-energy diet on lung tumor growth was greatly
attenuated with oral administration of metformin and was associated with reduced signaling
through the IR. Both the high-energy and control groups of mice displayed activation of
AMPK in tumor tissue, but only the high-energy group displayed significant reductions in
tumor growth suggesting AMPK independent mechanisms (100).
Thus the potential anti-tumorigenic properties of metformin may be attributed to both
“direct” and “indirect” mechanisms. Indirect mechanisms of action include overall reductions
in systemic insulinemia, bringing both glucose and insulin to physiologically normal plasma
levels. This could attenuate signaling through the insulin receptor and attenuate growth of
insulin responsive tumors. A primary “direct” class of proposed mechanisms requires
activation of LKB1 and downstream target AMPK in neoplastic cells. A simplified model of
this mechanism involves activation of this pathway and a subsequent suppression of
protein synthesis through inhibition of mTOR, though the downstream effectors of AMPK
are vast, and AMPK mediates many inhibitory effects on multiple signaling pathways. An
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interesting question lies in whether or not non-diabetic patients will have the same reduction
in cancer risk as their diabetic counterparts with metformin treatment.

1.5 Two-stage murine model of skin carcinogenesis and PI3K/Akt/mTOR pathway
The multistage or “two-stage” model of chemical carcinogenesis in mouse skin is a wellestablished in vivo tumor model system used to evaluate the consecutive or step-wise
process that gives rise to tumor development in the skin (Figure 1-6). Many epithelial
cancers (e.g. colon, breast, prostate) found in humans result from a multistage process
(101) making it relevant to address tumor development in a sequential, stage-oriented
manner. Strengths of the model include its ability to distinguish between initiation,
promotion, and progression phases of tumor development as well as the convenient ability
to visualize tumor growth throughout the lifespan of the mouse. Due to a highly reproducible
tumor response, the model is particularly useful for studying the effects of dietary energy
balance manipulation as well as pharmacological intervention via various chemopreventive
agents (both synthetic and natural) on tumor development. These pharmacological
inhibitors can also be used to determine the importance of specific signaling pathways
during each stage. The model may also be super-imposed on genetically engineered
mouse models (GEMMs) to help identify proto-oncogenes and tumor suppressor genes as
well as to determine susceptibility.
This multistage process begins with an irreversible single sub-carcinogenic topical
dose of a mutagenic agent. While a large range of “initiating” agents are used, currently the
most common agent employed is the polycyclic aromatic hydrocarbon 7-12dimethlybenz[a]anthracene (DMBA). This stage is referred to as the “initiation” stage and
gives rise to genetic lesions found in both follicular and interfollicular stem cells in the skin
(102, 103). The Hras1 gene has been found to be the primary target gene during this stage,
although there is evidence for mutations in Kras as well after exposure to DMBA and
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initiating agent N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) (101). Following the initiation
stage, promotion then occurs through clonal expansion of the mutated population of cells
via repeated topical application of chemical agents that cause overall increases in
proliferation and result in epidermal hyperplasia. In addition, initiated cells are thought to
have a growth advantage allowing for their selective expansion (104, 105). Common tumor
promoting agents include phorbol ester compounds of which the most frequently used is
12-O-tetradecanoylphorbol-13-acetate (TPA). TPA activates Protein Kinase C (PKC) which
mediates signaling through the Epidermal Growth Factor Receptor (EGFR) and has been
shown to induce cellular proliferation through activation of the Akt signaling cascade (106).
Promoting agents can also stimulate a host of pathways including PKC leading to increases
in cellular growth and proliferation through stimulation of EGFR and may also influence
inflammatory cell infiltration and oxidative stress. Repeated application of tumor promoting
agents eventually results in exophytic growths on the skin referred to as “papillomas” which
consist of a stromal core and are surrounded by hyperplastic tissue. Promoting agents are
usually applied two or more times per week and must be consistent as promotion at this
stage can be reversible causing papillomas to regress if treatment is not maintained.
Although timing is dependent upon the strain of the mouse used, papillomas can generally
be seen after 10 weeks of promotion. Eventually these benign outgrowths may progress to
the highly vascularized, downward invading malignant squamous cell carcinomas (SCCs)
as early as 20 weeks after promotion due to the additional accumulation of genetic
alterations which include trisomies of chromosomes 6 and 7 and mutations in p53 in these
small tumors (101).
While this model has several advantages over “complete” skin tumor models in
which a single carcinogen is used or continuous UV exposure is applied, there are a few
limitations to this model system that must be addressed. In this protocol, the mice present
a Hras driven model of tumorigenesis, whereas p53 appears to be the most important
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target gene in non-melanoma skin cancer in humans (107). Primary gene targets of this
model system appear to be more relevant to other human epithelial cancers some of which
include cancers of the lung, pancreas and colon (108). Additionally, there is no direct
human equivalent for a “papilloma.” However, SCCs that arise from malignant conversion
histologically favor those seen in humans as they are highly vascularized and invasive
(101). And lastly, this model has very low rates of metastasis, making it only useful for
studying primary tumors (109).

Figure 1-6

Figure 1-6 Schematic of two-stage murine model of skin carcinogenesis. Initiation
occurs with a single, topical sub-carcinogenic dose of a mutagenic agent followed by
repeated topical applications of a promoting agent two weeks after initiation. Promotion
continues for the entirety of the study. Papillomas begin to development 6-12 weeks after
promotion begins and a small fraction eventually converts to SCCs beginning approximately
20 weeks after promotion. This panel shows representative H&E stains of normal epidermis
followed by hyperplastic epidermis, a papilloma and a SCC. Reprinted by permission from
Macmillan Publishers Ltd: [Nature Protocols] (101), copyright 2009
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There is much evidence to suggest that signaling downstream of IGF-1R and
various other growth factor receptors to Akt and mTOR are primary mediators of tumor
promotion during epithelial carcinogenesis in mouse skin. In the BK5.IGF-1 transgenic
mouse model in which the bovine keratin 5 (BK5) promoter drives IGF-1 overexpression in
the epidermis, increased susceptibility to two-stage skin carcinogenesis, and spontaneous
tumor formation occurred. This was also associated with increased signaling through
PI3K/Akt and progression through the cell cycle as seen through upregulation of cell cycle
regulatory proteins in the epidermis (110, 111). The PI3K inhibitor LY294002 inhibited the
observed changes in this signaling pathway in the epidermis, and furthermore, it inhibited
skin tumor promotion in a dose dependent manner upon topical application (110). These
IGF-1 transgenic mouse studies support the role of PI3K and Akt in IGF-1’s role during skin
tumorigenesis. Additional studies further support a role for Akt during skin carcinogenesis.
Segrelles et al., reported that epidermal Akt activation was sustained through the duration
of the two-stage protocol in mouse skin (112). Additional studies have further confirmed the
importance of Akt signaling and cellular proliferation during skin tumor promotion using
transgenic mice that overexpress Akt1wt or Akt1myr in the epidermis under control of the BK5
promoter and found that deregulation of Akt expression and subsequent altercations in
related signaling pathways significantly heightened tumor response and resulted in the
generation of spontaneous tumors in both transgenic mouse models (113). The Akt1myr
mice have a permanently activated form of Akt through a myristoylation sequence located
in the basal layer of the epidermis while the Akt1wt mice express wildtype Akt in the basal
layer of the epidermis (113). In addition to enhanced tumorigenesis through activation of
the IGF-1/PI3K/Akt pathway, a marked increase in downstream target mTORC1 was also
observed in these mice in response to TPA treatment (106, 113). These data suggest that
mTORC1 activation may represent an important downstream Akt target and event during
skin tumor promotion.
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1.6 Hypothesis and Specific Aims
The overall goal of this project was to determine the contribution of mTORC1 to epithelial
carcinogenesis, specifically during skin tumor promotion using the two-stage model of
epithelial carcinogenesis in mouse skin across a range of weight phenotypes. Previous
published work from our lab has demonstrated that deregulation and overexpression of Akt
in the epidermis leads to enhanced susceptibility to chemical carcinogenesis in mouse skin
and generation of spontaneous tumors. Aberrant Akt activity in the epidermis also leads to
activation of many downstream effectors of Akt including GSK3β, Bad, and mTORC1 (113).
In addition, published data from our lab have shown that DIO and CR differentially modulate
the activity of Akt and mTOR in several tissues including the epidermis, and liver-specific
IGF-1 deficiency (LID), which results in decreased circulating levels of IGF-1, has been
shown to inhibit skin tumor promotion by TPA in mice (18, 43). These data suggest that the
differential effects of DIO/CR on Akt and mTOR signaling pathways are mediated partially
through IGF-1 and insulin responses. While previous data have shown aberrant activation
of Akt during skin tumor promotion and differential regulation of this pathway across the
DIO/CR spectrum, specific studies have not been completed to evaluate the independent
impact of mTORC1 during tumorigenesis across the spectrum of dietary energy balance in
the two-stage model of epithelial carcinogenesis. In this project, we used pharmacological
approaches to target mTORC1 in this well-characterized model to test our hypothesis that
mTORC1 signaling plays an important role in tumor promotion and plays an
important role in dietary energy balance effects on tumor promotion. mTORC1 is a
key target for preventing/controlling obesity related cancers. Selectively targeting
mTORC1 will offset the tumor-enhancing effects of obesity and produce calorie
restriction mimetic effects.
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Specific Aim 1: To determine the effect of rapamycin in control, overweight, and
obese mice during TPA skin tumor promotion. Two-stage skin carcinogenesis
experiments were completed to examine the impact of mTORC1 inhibition via rapamycin on
skin tumor promotion across a range of weight phenotypes via dietary manipulation to test
the hypotheses that pharmacological strategies targeting mTORC1 can inhibit skin tumor
promotion and offset the effects of overweight and obesity. The findings in this aim will
support future translational studies targeting this pathway for the prevention and control of
human epithelial cancers.

Specific Aim 2: To determine the impact of metformin on skin tumor promotion by
TPA. The effects of AMPK activation and mTORC1 inhibition via anti-diabetic drug
metformin on skin tumor promotion were evaluated during two-stage skin carcinogenesis
experiments. Metformin was administered via the drinking water during the skin tumor
promotion stage to overweight and obese mice either alone or in combination with
rapamycin. The goal of this aim was to find an agent that could be administered either
alone or in combination with rapamycin to target the mTORC1 pathway without dose
limiting toxic effects such as drastic deregulation of carbohydrate metabolism. The findings
in this aim are significant as they provide evidence that metformin may be more effective in
an obese rather than a normal weight population.

Specific Aim 3: To determine the mechanisms for the effects of rapamycin and
metformin on skin tumor promotion by TPA. The effects of both compounds on TPAinduced epidermal hyperproliferation and inflammation were evaluated as well as TPAinduced epidermal signaling through the Akt/mTORC1 pathway as well as other relevant
pathways. In addition, the effects of metformin on circulating serum levels of energy
balance related hormones and glucose tolerance were evaluated.
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Chapter 2: Materials and Methods
Antibodies, Chemicals and Reagents
A complete list of antibodies used is located in Table 1. Antibodies were supplied from BD
Biosciences (San Diego, CA), CalBioChem (EMD Millipore) (Darmstadt, Germany),
Cayman Chemical Co. (Ann Arbor, MI), and Cell Signaling Technologies (Danvers, MA).
Chemiluminescence detection kits were purchased from Pierce (Rockford, IL). 7,12dimethylbenz(a)anthracene (DMBA), Bromodeoxyuridine (BrdU), Metformin (1-1Dimethylbiguanide hydrochloride), proteinase inhibitor cocktails, phosphatase inhibitor
cocktails, anti-actin as well as anti-mouse and anti-rabbit secondary antibodies were
purchased from Sigma-Aldrich (St. Louis, MO). TPA was purchased from Alexis
Biochemicals (Plymouth Meeting, PA). Rapamycin was purchased from LC Laboratories
(Woburn, MA) (114).

Mouse Housing and Animal Care
All housing and mouse procedures were carried out in accordance with the guidelines
established by the Institutional Animal Care and Use Committee. Mice were fed ad libitum
and group housed for the duration of these studies.

Dietary Regimens
For preliminary studies, to achieve a normal weight range, mice were placed on a regular
chow diet. For dietary energy balance studies, diets were purchased in pellet form from
Research Diets, Inc. (New Brunswick, NJ) (Table 2). Upon arrival, mice were placed on the
semipurified control diet (10 kcal% fat, # D12450B) for a one week equilibrium period after
which they were randomized into one of two dietary treatment groups: control/overweight
(10 kcal% fat), fed ad libitum, or DIO (60 kcal% fat, # D12492), fed ad libitum. The precise
compositions of these diets are found in table 2. Before treatment protocols began, mice
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remained on diet for 8 weeks, or until statistically significant weight differences between the
groups were achieved.

Table 1
Protein

Company

Catalog #

4E-BP1 (Ser65), phospho

Cell Signaling Technologies

9451

4E-BP1 (Thr37/46), phospho

Cell Signaling Technologies

2855

Acetyl-CoA Carboxylase

Cell Signaling Technologies

3662

Acetyl-CoA Carboxylase (Ser79), phospho

Cell Signaling Technologies

3661

Akt

Cell Signaling Technologies

9272

Akt (Thr308) (D9E)XP®, phospho

Cell Signaling Technologies

4056

Akt (Ser473) (D9E)XP®, phospho

Cell Signaling Technologies

4060

AMPKα

Cell Signaling Technologies

2532

AMPKα (Thr172), phospho

Cell Signaling Technologies

2531

Beclin-1

Cell Signaling Technologies

3738

COX-2

Cayman Chemicals

LC3B XP®

Cell Signaling Technologies

3868

LKB1

Cell Signaling Technologies

3050

mTOR

Cell Signaling Technologies

2971

mTOR (Ser2448), phospho

Cell Signaling Technologies

2976

NFҡB p65

Cell Signaling Technologies

3034

NFҡB p65 (Ser536), phospho

Cell Signaling Technologies

3033

p27/kip1

BD Biosciences

p70S6K

Cell Signaling Technologies

9202

p70S6K (Thr389), phospho

Cell Signaling Technologies

9234

PDCD4 XP®

Cell Signaling Technologies

9535

PRAS40 XP®

Cell Signaling Technologies

2691

PRAS40 (Thr246)

Cell Signaling Technologies

2997

S6 Ribosomal Protein (Ser235/236), phospho

Cell Signaling Technologies

2211

S6 Ribosomal Protein (Ser240/244), phospho

Cell Signaling Technologies

2215

ULK1 (Ser555), phospho

Cell Signaling Technologies

5869

ULK1 (Ser757), phospho

Cell Signaling Technologies

6888

Table 1 List of Antibodies Used
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160126

610242

Table 2

Research diets

Protein
Carbohydrate
Fat
kcal/g
Ingredient
Casein, 80 Mesh
L-Cystine
Corn Starch
Maltodextrin 10
Sucrose
Cellulose, BW200
Soybean Oil
Lard
Mineral Mix S10026
DiCalcium Phosphate
Calcium Carbonate
Potassium Citrate, 1 H2O
Vitamin Mix V10001
Choline Bitartrate
FD&C Yellow Dye #5

D12450B
Control

D12492
DIO

gram% (kcal%)
19.2
(20)
67.3
(70)
4.3
(10)
3.85

gram% (kcal%)
26.2
(20)
26.3
(20)
34.9
(60)
5.24

gram%
200
3
315
35
350
50
25
20
10
13
5.5
16.5
10
2
0.05

gram%
200
3
0
125
68.8
50
25
245
10
13
5.5
16.5
10
2
0.05

Table 2 Nutritional composition of diets used. Distribution of protein, carbohydrate, fat
and ingredient content across the two dietary groups used in dietary energy balance
studies. Adapted from Research Diets Inc. product information, 2006.
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Treatment Regimens
Female FVB/N mice 6-8 weeks of age were obtained from the National Cancer Institute and
group housed for the duration of the study in all experiments. For normal weight mice,
treatment protocols began immediately. For dietary energy balance studies, treatments
began after 7-8 weeks on various diets. In order to evaluate various protein markers and
signaling in the epidermis, groups of 5-6 mice each were dorsally shaved and treated twice
weekly for two weeks (i.e. 4 treatments total) with acetone vehicle (0.2 ml), 6.8 nmol of
TPA, or various doses of pharmacological inhibitors, rapamycin or metformin. Similar single
treatment experiments were also conducted. Rapamycin was dissolved in 0.2 ml of acetone
vehicle at doses ranging between 1000 nmol and 2 nmol. For metformin treatment
experiments, metformin was administered via the drinking water at the start of the two-week
treatment period at doses of 50, 250 or 350 mg/kg body weight per day. It was assumed
that each mouse consumed approximately 5 ml of water per day. The metformin treated
water was replaced twice weekly and adjusted for changes in body weight every two
weeks. Mice were sacrificed 6 hours after final acetone or TPA treatment and pooled
epidermal protein lysates were prepared. To histologically evaluate short term markers of
skin tumor promotion including epidermal hyperplasia and labeling index (LI), as well as
immune cell infiltration, the dorsal skin of mice was shaved and treated. BrdU was
administered via i.p. injection (100 g/g body weight) in 0.9% NaCl 30 min prior to sacrifice.
Mice were sacrificed 48 hours after the last treatment. Dorsal skin samples were fixed in
10% neutral buffered formalin, stored in 70% ethanol, embedded in paraffin and then
sectioned. Sections were cut and stained with H&E, anti-BrdU, or antibodies against LY6G,
S100A9, or CD3. Epidermal thickness and labeling index were determined as described
previously (115). Dermal immune cell infiltration was determined by the number of positive
stained cells per 200 µm2 field (24 fields per slide) (114).
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Two-Stage Skin Carcinogenesis (Normal Weight)
Groups of 15-20 female FVB/N mice between 7-9 weeks of age on a regular chow diet
were used. 48 hours prior to initiation, the dorsal skins of mice were shaved. Mice were
initiated with either a topical application of 25 nmol of DMBA dissolved in 0.2 ml acetone
applied to the dorsal skin, or received 0.2 ml vehicle (acetone). Two-weeks after initiation,
mice received treatment with various doses of rapamycin administered topically (2 nmol200 nmol) in 0.2 ml acetone or vehicle (acetone) 30 min prior to promotion with 6.8 nmol of
TPA in 0.2 ml acetone. This treatment protocol was continued twice weekly until tumor
multiplicity plateaued ( i.e.25 weeks). For regression tumor studies, groups of mice did not
receive inhibitor treatment for 15 weeks, in which time skin tumors were generated. Mice
were then treated with various doses of topical rapamycin (20 nmol and 100 nmol) with or
without continued TPA treatment. Tumor incidence (percentage of mice with papillomas),
tumor multiplicity (average number of papillomas per mouse), and mouse weight were
recorded weekly for the entirety of the studies (114).

Two-Stage Skin Carcinogenesis (Overweight and Obese)
For diet based tumor studies, mice were initiated with 25 nmol of DMBA or acetone as
previously described and were placed on a 10 kcal% fat diet for a two-week equilibrium
period and then either continued on this diet, or were placed on the DIO diet (60 kcal % fat),
fed ad libitum. After 6-8 weeks on the experimental diets mice began treatment with various
doses of topical rapamycin dissolved in 0.2 ml acetone or began metformin treatment
administered in the drinking water. This was followed by promotion for 25 weeks with 6.8
nmol of TPA twice weekly. Tumor multiplicity, tumor incidence, and mouse weight were
recorded each week for the duration of the study. To evaluate the effect of inhibitors on
progression (conversion of papillomas to squamous cell carcinomas) treatment protocols

31

were continued until week 50. During this time carcinoma number and conversion ratios
were recorded. Counts were verified histologically by a blinded pathologist.

Preparation of Epidermal Lysates
Upon sacrifice, a depilatory agent was applied to mouse dorsal skin for 30 s and removed
under cool, gently running water. The skin was then excised, and the epidermal layer was
removed by scraping with a razor blade into prepared lysis buffer (50 mM Tris-HCl pH 7.4,
150 mM NaCl, 1 mM EDTA, 1 mM sodium orthovanadate, 1% NP-40, phosphatase inhibitor
cocktail 1 and 2, proteinase inhibitor cocktail) and then homogenized using an 18-gauge
needle. Epidermal scrapings were pooled from 3-6 mice to generate an epidermal protein
lysate. These lysates were spun at 14,000 RPM for 15 min, and supernatant was removed.
This process was repeated, and the collected supernatant was snap frozen in liquid
nitrogen and stored at -80°C until analysis (114).

Western Blot Analysis and Immunoprecipitation
Protein concentration was determined using the DC (detergent compatible) protein assay
from Bio Rad (Lowry). For western blot analysis, 50-75 µg of protein lysate per lane was
used. Epidermal protein lysate was electrophoresed in 4-15% SDS-PAGE gels and then
transferred onto nitrocellulose membranes (BioRad, Hercules, CA). The criterion precast
gel system was utilized (BioRad, Hercules, CA). Membranes were blocked for 1 h in 5%
bovine serum albumin (BSA) in TBS with 1% tween (TTBS) and incubated overnight at 4C
with designated antibodies found in Table 1. The membranes were then washed 3 times for
10 min each in TTBS prior to incubation with secondary antibodies for 1 h at room
temperature. Additional washes (3 washes, 10 min each) were done to remove unbound
secondary antibody, and protein bands were then visualized using a chemiluminescence
detection kit (Pierce ECL Western Blotting Substrate, Rockford, IL) (114). For experiments
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requiring quantitation, film was scanned manually and densitometry was performed using
AlphaView Software: Protein Simple (Santa Clara, CA). Westerns were normalized by
dividing the phosphorylated protein density by the total protein density or total actin, and the
acetone control was set to 1. For co-immunoprecipitation experiments, epidermal lysates
were prepared from CHAPS lysis buffer (30 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1%
CHAPS) and were precipitated with raptor (cell signaling) antibody using Dynabead Protein
G IP kit (Invitrogen, Carlsbad, CA), and blots were probed for mTOR and raptor (Cell
Signaling, Danvers, MA).

Serum Analysis
Blood was collected from individual mice immediately following CO2 asphyxiation via
cardiac puncture (7-8 mice per treatment/diet group). Blood was allowed to sit at RT for 2
hours and then spun at 7,500 rpm for 7 min. Supernatant was collected and spun again
under the same conditions. Serum was then collected and flash frozen in liquid nitrogen
and stored at -80° until analysis. Serum levels of insulin and leptin were measured using a
10 µl sample with a Milliplex MAP Mouse Serum Adipokine panel multiplex Luminex Assay
(Millipore, Darmstadt, Germany). Serum adiponectin levels were measured using a 10 µl
sample with a Milliplex MAP Mouse Serum single plex Luminex Assay (Millipore,
Darmstadt, Germany).

Glucose Tolerance Test
Glucose tolerance tests were performed at week 20 during a diet based tumor study from a
randomly selected subset of mice from each treatment/diet group (n=10). Mice were fasted
for 12 hours and 20% glucose (2 g/kg body weight via IP) was administered. Blood samples
were taken from the tails, and glucose levels were determined at baseline, 30, 60, 90, and
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120 min after injections of glucose using the Ascencia Elite XL 3901G Glucose Analyzer
from Bayer Corporation (Pittsburgh, PA).

Statistical Analyses
Labeling index (% BrdU positive cells), epidermal thickness (m), and dermal immune cell
infiltration (positive cells per field) were presented as the mean + the standard error of the
mean, and mean differences were analyzed with the Mann-Whitney U-test. To determine
minimal sample size for two-stage skin carcinogenesis and diet studies, power calculations
were completed using GraphPad Statmate (Lo Jolla, CA).To compare tumor incidence in all
two-stage studies, the 2 test was used. For comparison of tumor multiplicity in two-stage
studies, the Mann-Whitney U-test was again used. Differences in serum levels were
analyzed using the Mann-Whitney U-test. GraphPad prism was used for all tests unless
otherwise noted, and significance was set at P<0.05 in all cases.
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Chapter 3-Rapamycin Potently Inhibits Skin Tumor Promotion by TPA in Normal
Weight, Overweight, and Obese Mice
As previously discussed in the Introduction, earlier work from our lab as well as others,
suggest that signaling through the PI3K/Akt/mTOR pathway plays a crucial role during
epithelial carcinogenesis, specifically during skin tumor promotion by 12-Otetradecanoylphorbol-13-acetate. During this process, activation of epidermal Akt occurs as
well as many downstream Akt effectors including mTORC1. In addition, differential
signaling through this pathway across the CR/DIO spectrum has been revealed in a variety
of epithelial tissues further supporting the hypothesis that pathways activated in diabetic
and high IGF-1 states (such as in DIO) may be the key targets for preventing obesity-driven
cancers. While it is clear that deregulated Akt signaling is associated with development and
progression of many types of human cancers, Akt’s downstream effectors mediating much
of these effects has not been as well defined. Because of mTORC1’s central role in linking
energy and nutrient status to growth factor signaling and subsequent protein synthesis, it
was hypothesized that mTORC1 plays a primary role during skin tumor promotion, and its
activation and/or repression might be a key mediator between dietary energy balance
effects during skin tumorigenesis. In addition, it was hypothesized that pharmacological
disruption of mTORC1 may block the harmful effects of DIO and a high-energy diet as well
as replicate the benefits associated with CR. In order to address this question, initial
experiments were carried out to assess the ability of established mTORC1 inhibitor,
rapamycin to block skin tumor promotion by TPA. These experiments utilized female wildtype mice (FVB/N) that were either a normal weight (regular chow diet), overweight (10
kcal% fat), or obese (DIO, 60 kcal% fat). FVB/N mice were chosen as an appropriate strain
for these studies. Using an inbred strain helps reduce variability in tumor development. In
addition, this strain of mice is moderately sensitive to TPA as a skin tumor promoting agent,
typically reaching between 20-100% tumor incidence and up to 11.8 papillomas per mouse
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when using DMBA (19.5 to 390 nmol) and TPA (0.8 to 8.0 nmol) (101). In all cases, female
mice were used to reduce aggressive behavior and allow for group housing.

3-1 Effect of rapamycin on skin tumor promotion in normal weight mice
Two-stage skin carcinogenesis experiments in FVB/N mice were completed to
assess inhibitory effects of rapamycin on skin tumor promotion in normal weight mice.
These studies were designed to establish baseline effects of rapamycin on skin tumor
promotion as well as provide appropriate doses of rapamycin to be applied topically for use
in subsequent dietary energy balance studies.
Groups of female FVB/N mice 7-8 weeks of age were initiated with 25 nmol
of DMBA, and then 2 weeks later, treated topically with various doses of rapamycin
(5-200 nmol) or acetone vehicle followed 30 min later by 6.8 nmol of TPA. All
treatments were given twice weekly for the duration of the experiment (25 weeks).
Tumor incidence (percentage of mice with papillomas) and tumor multiplicity were
measured weekly for each group. As shown in Figure 3-1A, rapamycin exerted a
powerful anti-promoting effect. Treatment groups receiving topical application of
200, 100, or 50 nmol of rapamycin 30 minutes prior to application of TPA, had
complete inhibition of papilloma development (Figure 3-1A). In addition, there was
also a significant reduction in papilloma development in the groups receiving 20
nmol and 5 nmol doses of rapamycin compared to the DMBA-TPA only control
group. In this regard, at week 25 a 92% inhibition of papilloma development was
observed in the group receiving 20 nmol of rapamycin prior to TPA, and a 49%
inhibition of papilloma development was observed in the group receiving 5 nmol of
rapamycin prior to TPA (P<0.05, Mann-Whitney U ) (see again Figure 3-1A). No
papillomas developed in the groups initiated with DMBA followed by twice weekly
treatments with either acetone or 200 nmol of rapamycin. In addition, we did not
observe a significant number of SCCs in any of the groups at the end of the tumor
experiment, consistent with previous studies from our laboratory that used an even
higher initiating dose of DMBA (116). These studies showed that most SCCs
developed in FVB/N mice after 25 weeks of promotion.
Tumor latency was also affected in groups treated with 20 nmol and 5 nmol
of rapamycin prior to treatment with TPA. The time to 50% incidence of papillomas
in the TPA promotion control group was 10-11 weeks versus 16-17 weeks in the 5
nmol rapamycin treated group (Figure 3-1B). Mice in the 20 nmol rapamycin
pretreated group reached only 32% tumor incidence as determined at week 25
(Figure 3-1B). Differences in tumor latency were statistically significant (P<0.05, 2
test). These data clearly show that rapamycin was a potent inhibitor of TPA skin
tumor promotion, dramatically reducing both tumor multiplicity and tumor incidence
and altering latency in a dose-dependent manner.
On the basis of the data in Figures 3-1A and 3-1B showing that rapamycin
dramatically inhibited the promotion of skin tumors, an experiment was conducted to
determine whether topical treatments of rapamycin would inhibit growth of existing
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papillomas generated by the two-stage protocol. For this experiment, female FVB/N
mice 7-8 weeks of age were initiated with 25 nmol of DMBA and promotion was
begun two weeks later with 6.8 nmol of TPA. Promotion was continued twice-weekly
for 15 weeks. At week 15, mice were randomized into groups that received topical
applications of 100 nmol or 20 nmol of rapamycin alone, acetone alone, or
rapamycin treatments (100 nmol and 20 nmol) 30 minutes prior to continued
promotion with 6.8 nmol of TPA. All treatments continued until week 25. Tumor
multiplicity and tumor incidence were determined each week. As shown in Figure 31C, topical treatment of rapamycin induced regression or inhibited growth of existing
skin tumors. All groups receiving acetone or a dose of rapamycin with or without
continued promotion with 6.8 nmol of TPA had statistically significant reductions in
tumor multiplicity compared to the group that continued with just 6.8 nmol TPA
treatments alone (P< 0.05, Mann Whitney U). At week 25 there was a 48%
reduction of papilloma development in the acetone treated group compared to the
6.8 nmol treated group (Figure 3-1C). There was a 74% inhibition in the group
receiving 100 nmol of rapamycin alone and a 67% inhibition in the group receiving
100 nmol of rapamycin prior to 6.8nmol of TPA (Figure 3-1C). There was a 75%
inhibition of papillomas in the group receiving 20 nmol of rapamycin alone and a
49% inhibition in the mice receiving 20 nmol of rapamycin prior to treatment with 6.8
nmol of TPA (Figure 3-1C). There were no statistically significant differences in
tumor incidence (data not shown). These data indicate that, in addition to
dramatically preventing the formation of skin tumors, topically applied rapamycin
inhibited growth and/or induced regression of existing papillomas even in the
presence of continued TPA treatment. [Reprinted from (114)]

The experiment in Figure 3-1A and B was repeated using similar doses of
rapamycin and promoted with 6.8 nmol of TPA for 23 weeks (Figure 3-2A). Results were
close to those found in Figures 3-1A and 3-1B. Time to 50% incidence was 10-11 weeks in
the TPA control group versus 15-16 weeks in the 5 nmol rapamycin treatment group (Figure
3-2C). There was an 85% inhibition of papilloma development in the 5 nmol rapamycin
treatment group and complete inhibition at 200,100, and 50 nmol of rapamycin (Figure 32B). Mouse weight gain was recorded every two weeks for the duration of the study to
monitor for any possible toxicity present with rapamycin treatment. Topical rapamycin
treatment had no effect on body weight gain in any of the experimental treatment groups for
the duration of the study (Figure 3-3).
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Figure 3-1

Figure 3-1 Effect of rapamycin treatment on skin tumor promotion by TPA in normal
weight mice. Female FVB/N mice 7-8 weeks of age were initiated with 25 nmol of DMBA.
Two weeks following initiation, mice were treated topically twice weekly with various
rapamycin doses or acetone, followed by promotion with 6.8 nmol TPA for 25 weeks. A)
Tumor multiplicity: Differences in the average number of papillomas per mouse at 25 weeks
between 20 nmol (●), 5 nmol (▲) rapamycin treated groups and the corresponding 6.8 nmol
TPA () treated group were statistically significant (*P<0.05,***P<0.001, respectively,
Mann-Whitney U). B) Differences in tumor incidence at 25 weeks between the 20 nmol (●)
rapamycin group and the 6.8 nmol TPA () group were statistically significant (**P<0.01,2test). C) Female FVB/N mice 7-8 weeks of age were initiated with 25 nmol of DMBA and
two weeks following initiation, promotion began with 6.8 nmol of TPA. After 15 weeks of
promotion, mice were randomized to receive either 100 or 20 nmol of rapamycin or acetone
either alone or followed by treatment with 6.8 nmol TPA. Differences in tumor multiplicity
were statistically significant between the rapamycin treated groups and TPA treated group.
Acetone (●) and 20 nmol rapamycin + TPA () groups (*P<0.05), 100 nmol rapamycin +
TPA () (**P<0.01), 20 nmol rapamycin () and 100 nmol rapamycin (---) (***P<0.0001;
Mann-Whitney U). [Reprinted from (114)]
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Figure 3-2

A

B

C

Figure 3-2 Confirmation of rapamycin’ s potent inhibitory effects on skin tumor
promotion by TPA. A two-stage skin carcinogenesis study was repeated to confirm the
previous potent reductions seen after topical administration of rapamycin on tumor
development. A) Treatment protocol: Mice were initiated with 25 nmol of DMBA. Treatment
with rapamycin and promotion with TPA began two weeks later. Treatment protocols
continued for 23 weeks. B) Tumor multiplicity: Differences in the average number of
papillomas per mouse at week 23. C) Tumor Incidence: Differences in the percent of mice
with papillomas at week 23.
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Figure 3-3
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Figure 3-3 Weight gain of mice during two-stage skin carcinogenesis experiments
with topical rapamycin treatment. There were no significant differences in weight gain
across the various acetone, TPA and rapamycin treatment groups for the duration of the 23
week study.

3.2 Effect of rapamycin on skin tumor promotion in overweight and obese mice
The previous experiments provided substantial evidence supporting mTORC1’s contribution
to the process of skin tumor promotion, as rapamycin exerted a powerful anti-promoting
effect. Therefore, the ability of rapamycin to reverse the effects of overweight and obesity
on tumor development and augment the anticancer benefits of CR in the two-stage model
of murine skin carcinogenesis was examined. Inhibition of tumor development with
rapamycin in these dietary manipulated groups would also complement previous data from
our lab supporting mTORC1’s importance in dietary energy balance effects during skin
tumorigenesis. For these experiments female FVB/N mice 7-8 weeks of age were initiated
with 25 nmol of DMBA. After a two week equilibrium period on control diet, they either
continued on this control diet (10 kcal % fat ) fed ad libitum or began DIO via the high fat
diet (60 kcal % fat) fed ad libitum for the duration of the studies. While Research Diets
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DI2450B semipurified diet is noted as a “control” diet, previous studies in our lab as well as
others (117) have noted that this diet leads to overweight female FVB/N mice as well as
C57BL/6nCr based on appropriately corresponding Body Mass Index.
Promotion during these two-stage studies began after 6 weeks on each
experimental diet, after which differences in body weights between the two diet groups had
reached statistical significance (Figure 3-4D). Mice were treated topically with 20 nmol or 5
nmol of rapamycin 30 min prior to promotion with 6.8 nmol of TPA. All treatments were
administered twice weekly for the duration of the experiment. Tumor incidence (percentage
of mice with papillomas) and tumor multiplicity (average number of papillomas per mouse)
were measured weekly for each group. As shown in Figure 3-4B, rapamycin potently
inhibited skin tumor promotion by TPA in the overweight mice. In this regard, groups
receiving 5 nmol of topical rapamycin treatment prior to TPA, displayed an 88% reduction in
papilloma development at week 25 as compared to the DMBA-TPA control group (P< 0.05;
Mann –Whitney U). In addition, the 20 nmol rapamycin treatment + TPA group had a 97%
reduction in papilloma development (P< 0.05; Mann –Whitney U). The 20 nmol rapamycin
treatment + TPA group only resulted in 23% incidence, and the 5 nmol rapamycin treatment
+ TPA group reached just 43% incidence (Figure 3-4C). Additionally, this diet group was
carried out to the progression phase of skin carcinogenesis. Carcinomas were counted
weekly, and the average number of carcinomas and conversion ratios were recorded.
Treatment protocols continued as previously conducted during promotion and continued
until week 50. However, it should be noted that in contrast to papilloma development, the
development of SCCs during progression will likely cause mice to die. Thus, for this portion
of the tumor study SCC multiplicity and incidence were calculated cumulatively. All SCCs
from the tumor bearing mice were carried forward even after sacrifice. As expected,
rapamycin inhibited the conversion of papillomas to squamous cell carcinomas in a dose
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dependent manner corresponding to decreases in papillomas during skin tumor promotion
(Figure 3-5). Carcinoma development was verified histologically by a blinded pathologist.

Figure 3-4
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Figure 3-4 Effect of rapamycin treatment on skin tumor promotion by TPA in
overweight/control mice. Female FVB/N mice 7-8 weeks of age were initiated with 25
nmol of DMBA. A) Treatment protocol: At week 2, mice were placed on the 10 kcal% fat
diet, fed ad libitum. After 6 weeks on diet to allow for weight gain, topical rapamycin
treatment began followed 30 min later by promotion with 6.8 nmol TPA. Treatment protocol
was continued for 25 weeks. B) Tumor multiplicity: Differences in the average number of
papillomas per mouse at 25 weeks between 20 nmol (-), 5 nmol (●) rapamycin treated
groups and the corresponding 6.8 nmol TPA () were statistically significant,
(**P<0.01,*P<0.05, respectively, Mann-Whitney U). C) Differences in tumor incidence at 25
weeks between 20 nmol (-), 5 nmol (●) rapamycin group and the 6.8 nmol TPA () group
were statistically significant (***P<0.001,2-test). D) There were no statistically significant
differences in weight gain between any of the treatment groups.

Figure 3-5

Figure 3-5 Rapamycin decreases squamous cell carcinoma development in
control/overweight mice (10 kcal % fat). 1Data taken at 27 weeks of promotion with 6.8
nmol TPA after which the papilloma response had reached a plateau.2Ratio of the average
number of SCCs at 49 weeks to average number of papillomas at 27 weeks
a
Denotes significantly different from DMBA/TPA control; P<0.05, Mann Whitney U).
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In the obese mice, there were dramatic decreases in papilloma development and
tumor burden. In a similar protocol with the exception of the high-fat diet in place of
control/overweight diet, (Figure 3-6A), two-stage studies revealed potent inhibition of tumor
development in the obese mice. In addition, rapamycin appeared to be slightly more
effective in the obese mice with a 98% inhibition of tumor development in the 20 nmol
rapamycin + TPA treatment group and a 94% inhibition in the 5 nmol rapamycin + TPA
treatment group as compared to the DMBA-TPA control group (Figure 3-6B). In terms of
tumor incidence, there were also dramatic responses as the 20 nmol rapamycin treatment
group was just under 7% incidence at week 25, and the 5 nmol rapamycin treatment group
was just under 29% incidence (Figure 3-6C).
Rapamycin caused no significant decreases in overall body weight throughout the
duration of the study. There were however significant differences in overall body weight
between the overweight (33.9 + 1.90) and obese mice (44.9 + 0.84) as expected (P< 0.05,
Mann Whitney U), (Figure 3-4D and 3-6D).
The results presented in this chapter support previous findings that mTORC1 plays
an important role in skin tumor promotion. Data from previous two-stage carcinogenesis
experiments in our lab using transgenic Akt and IGF-I mice, overexpressing these proteins
in the epidermis support the hypothesis that Akt levels elevated in the epidermis increase
susceptibility to epithelial carcinogenesis. These mice displayed heightened epidermal
hyperproliferation as well as increases in mTORC1 activation in response to TPA treatment
(111, 113, 118). Lu and colleagues reported that activation of mTORC1 activator, Rheb led
to spontaneous skin tumor development in a DMBA-induced tumorigenesis model (119)
lending to additional overall support of this hypothesis. In addition, this data also support a
role for mTORC1 activation in the link between obesity and epithelial carcinogenesis
consistent with previous data. In terms of dietary energy balance, Moore and colleagues
demonstrated that dietary energy balance modulation results in differential signaling
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through the cell surface receptors, IGF-1R and EGFR and downstream substrates. In a
variety of epithelial tissues, DIO enhanced, while CR reduced signaling through these
receptors and downstream to Akt and mTOR (43). Another study showed that LID mice with
a 75% reduction in circulating levels of IGF-1 reduced skin tumor development in the twostage model of skin carcinogenesis and reduced activation of Akt and mTOR (18).
Overall, these findings show that rapamycin on a molar basis, is one of the most
effective inhibitors of skin tumor promotion to date. When rapamycin is topically applied to
mouse skin prior to promotion with TPA, it potently inhibits this stage in a dose-dependent
manner as well as inhibits growth of existing skin tumors. In addition, rapamycin appears to
reverse the effects of overweight and obesity on skin tumorigenesis and may be more
effective in these dietary energy balance groups.
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Figure 3-6
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Figure 3-6 Effect of rapamycin treatment on skin tumor promotion by TPA in obese
mice. Female FVB/N mice 7-8 weeks of age were initiated with 25 nmol of DMBA. A)
Treatment protocol: At week 2, mice were placed on the high fat diet, DIO (60 kcal% fat
diet, fed ad libitum. After 6 weeks on diet, topical rapamycin treatment began followed 30
min later by promotion with 6.8 nmol TPA. Treatment protocol was continued for 25 weeks.
B) Tumor multiplicity: Differences in the average number of papillomas per mouse at 25
weeks between 20 nmol (-), 5 nmol (●) rapamycin treated groups and the corresponding
6.8 nmol TPA () were statistically significant, (**P<0.01,*P<0.05, respectively, MannWhitney U). C) Differences in tumor incidence at 25 weeks between 20 nmol (-), 5 nmol (●)
rapamycin group and the 6.8 nmol TPA () group were statistically significant
(***P<0.001,2-test). D) There were no statistically significant differences in weight gain
between any of the treatment groups.

46

Chapter 4- Metformin Given in the Drinking Water Attenuates Skin Tumor Promotion
in Overweight and Obese Mice
The class of pharmacological agents targeting PI3K, Akt, and mTOR are not expected to be
highly tumor-specific and thus inhibition of this pathway in normal tissue as well as tumor
tissue is expected to occur in response to use of these therapies. Thus targeting PI3K or
signaling nodes downstream of this pathway has been associated with large systemic
effects including deregulation of carbohydrate metabolism and insulin signaling. This can
result in hyperglycemia due to decreases in glucose uptake by the muscles and
hyperinsulinemia (120). The subsequent insulin resistance that occurs may limit the efficacy
of the many PI3K and downstream inhibitors, including mTORC1 inhibitor rapamycin. In
addition, treatment with mTORC1 inhibitors such as rapamycin has been associated with
inhibition of the p70S6K-IRS-1 negative feedback loop. This mTORC1 dependent feedback
loops acts to inhibit activation of the PI3K/Akt pathway as IRS-1’s inhibitory sites are bound
by mTOR and p70S6K (70, 121). When pharmacological doses of mTORC1 inhibitors are
great enough to interrupt this feedback loop, activation of Akt occurs resulting in a limitation
of the antineoplastic effects of this class of inhibitors.
In the previous two-stage skin carcinogenesis experiments performed, rapamycin
was utilized as a topical treatment applied directly to the epidermis resulting in limited
systemic effects. In addition, despite the possibility of negative feedback loop inhibition, all
doses of rapamycin used caused significant decreases in tumor development as previously
shown in Chapter 3. However, other treatment options were explored targeting this pathway
that could be administered orally or in combination with rapamycin without efficacy
interference or dose-limiting toxicity. In addition, when using rapamycin, there was a large
decrease in inflammation associated with use of TPA possibly accounting for much of
rapamycin’s anti-cancer effects, thus studies were conducted to explore another mTORC1
inhibitor that might not have such dramatic effects on TPA-induced inflammation making it
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easier to attribute decreases in tumor burden to mTORC1 inhibition. The data displaying
rapamycin’s mechanisms of action are shown and discussed in more detail in Chapter 5.
The effect of the type II diabetes drug, metformin administered via the drinking water on
skin tumor promotion by TPA was investigated next. Many population based studies have
provided evidence that patients with type II diabetes treated with metformin have reduced
cancer incidence as well as reduced mortality (89, 90). In addition, a variety of in vitro and
in vivo studies have also supported this association.
As discussed in the Introduction, metformin inhibits gluconeogenesis and thus
lowers overall circulating levels of glucose and subsequently insulin, thereby treating
diabetes. It does this through activation of the LKB1/AMPK pathway in the liver. In contrast
to PI3K and downstream inhibitors, metformin’s mode of action should not interfere with
efficacy or disrupt normal metabolic function. In fact, it should attenuate the hyperglycemia
and insulinemia associated with PI3K/Akt/mTOR inhibitors and contribute to antineoplastic
activity either indirectly through its insulin lowering effects or directly through AMPK
activation and subsequent mTORC1 inhibition in cancer cells. Metformin treatment has also
been associated with decreases in Akt activation in many tumor types lending to its overall
efficacy (95, 96). This could further support its promising role as a monotherapy or in
combination therapies with the PI3K and downstream class of inhibitors.
Because most epidemiological data supporting metformin’s antineoplastic activity
was obtained from a diabetic population displaying high rates of hyperinsulinemia and
obesity, studies were designed specifically to evaluate the effectiveness of metformin in the
two-stage skin chemical carcinogenesis model system in obese mice. Obesity was
generated via administration of a high-fat diet (DIO, 60 kcal % fat) that elevated insulin
levels and caused dramatic weight gain. The control diet (10 kcal % fat) was considered to
cause mice to become modestly overweight. In addition, a dual targeting therapy was
designed in which metformin was administered in combination with rapamycin to test for an
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additive effect. Ideally, the effectiveness of this combination would be achieved with very
low doses of each compound.

4.1 Metformin administered via the drinking water attenuates TPA skin tumor
promotion in overweight mice
To evaluate the effect of oral administration of metformin via the drinking water on skin
tumor promotion by TPA in overweight mice, female FVB/N 6-7 weeks of age were initiated
with 25 nmol of DMBA. They continued on the overweight/control diet (10 kcal % fat) fed
ad libitum to generate an overweight phenotype for the duration of the studies. After a 6
week period on diet, metformin was added to the drinking water at doses of 50 mg/kg body
weight per day or 250 mg/kg body weight per day. Thus it could be assumed that a 30 g
mouse drinking approximately 5 mls of water per day would receive 1.5 mg of metformin
administered as 5 mls of a 0.30 mg/ml solution. These doses were chosen based on
previous data from the literature that demonstrated doses ranging from 50 mg/kg body
weight per day to 350 mg/kg body weight per day in the drinking water or diet was sufficient
to demonstrate antineoplastic effects in vivo (98-100, 122, 123). Additionally, in vivo data
also showed that much higher doses used actually had the opposite effect on tumor growth.
Phoenix and colleagues reported that metformin administered at 750 mg/kg body weight
per day increased tumor growth and angiogenesis in a xenograft model using ERα negative
MDA-MB-435 cells (124). This dose is about 45 fold the recommended human dose
administered (125). Promotion with 6.8 nmol of TPA applied topically was also begun at this
time (Figure 4-1A). Promotion with TPA was continued twice weekly for the duration of the
experiment and metformin was replaced fresh in the drinking water twice weekly. Tumor
incidence and tumor multiplicity were measured weekly for each diet/treatment group. As
shown in figure 4-1B, metformin at both doses significantly attenuated skin tumor promotion
in a dose dependent manner.

49

Figure 4-1

A

C

B
*
*

D

E
E

*
*

**

Figure 4-1 Metformin alone and in combination with rapamycin attenuates skin tumor
promotion in overweight mice. A) Female FVB/N mice 7-8 weeks of age were initiated
with 25 nmol of DMBA. Mice were then placed on the overweight/control diet (10 kcal %
fat). After 6 weeks on diet, mice were administered metformin via the drinking water and
promotion began with TPA. In experiments with combination treatments, 2 nmol of
rapamycin was applied topically 30 min prior to TPA. B) Differences in tumor multiplicity at
25 weeks between the metformin + TPA treated groups and the DMBA-TPA control group
were significantly different at both doses (*, P<0.05, Mann-Whitney U).C) Differences in
tumor incidence at 25 weeks were not statistically significant between any treatment
groups. D) Both the 50 mg/kg metformin + TPA group (--) and the combination treatment
group (ο) were statistically significant from the DMBA control group (■) in terms of tumor
multiplicity. E) Differences in tumor multiplicity between the combination treatment group (ο)
and the DMBA-TPA (■) control group were statistically significant (**, P<0.01, 2-test).
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In this regard, a 72% inhibition of papilloma development in the 250 mg/kg body weight per
day dose and a 36% inhibition in tumor development in the 50 mg/kg body weight per day
dose were observed after metformin treatment. While tumor latency was not affected with
either dose of metformin, there was a modest decrease in tumor incidence at the highest
dose used (Figure 4-1C). The DMBA-TPA control group displayed 91% tumor incidence as
compared to 69% incidence for the 250 mg/kg dose of metformin and 89 % incidence for
the 50 mg/kg dose of metformin. This tumor study was also carried out to carcinomas to
evaluate metformin’s effect on the conversion of papillomas to carcinomas and conversion
ratios. As expected, metformin decreased the number of squamous cell carcinomas in both
treatment groups in a dose dependent manner that corresponded to the average number of
papillomas recorded. Metformin also had no effect on the malignant conversion ratio
(Figure 4-2).

Figure 4-2

Figure 4-2 Metformin decreases the number of SCCs and does not alter the rate of
malignant conversion in overweight mice 1Data taken at 27 weeks of promotion with 6.8
nmol TPA after which the papilloma response had reached a plateau.2Ratio of the average
number of SCCs at 49 weeks to average number of papillomas at 27 weeks. aDenotes
significantly different from the DMBA/TPA control group. ( P<0.05, Mann Whitney U)
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This study was followed by a repeat two-stage skin carcinogenesis study with the
addition of a rapamycin/metformin combination treatment group. For this tumor experiment,
the effects of low doses of metformin and rapamycin alone or in combination on skin tumor
development were evaluated. There was approximately 52% inhibition of papilloma
development with the rapamycin/metformin + TPA combination treatment group compared
to the DMBA-TPA control group. This was more effective than either compound alone as 50
mg/kg metformin + TPA, similar to the initial experiment, displayed 34% inhibition, and the 2
nmol rapamycin + TPA displayed 19% inhibition of papilloma development (Figure 4-1D).
As in the previous tumor experiment, there were modest effects on tumor incidence with
each treatment regimen. There was 82% tumor incidence in the 2 nmol rapamycin + TPA
treated group, 89% incidence in the 50 mg/kg metformin + TPA treated group, and 72%
incidence in the combination treated group compared to 100% tumor incidence in the
DMBA-TPA control group (Figure 4-1E).
4.2 Metformin administered via the drinking water potently inhibits skin tumor
promotion by TPA in obese mice
During this experiment, a high fat diet group was also included to determine whether
metformin was more highly effective in the obese mice. In a similar treatment protocol
outlined in figure 4-4A, mice were initiated with 25 nmol of DMBA and then placed on the
control diet (10 kcal% fat) for a two week equilibration period. They were then placed on the
high fat diet (DIO, 60 kcal% fat) for the duration of the study. Weight distributions of both
the control/overweight 10 kcal% diet and the high fat, DIO 60 kcal % diet can be found in
Figure 4-3. The differences in average body weight between the two diet groups were
statistically significant as expected (P<0.05, Mann-Whitney U). However, within a given
diet, neither metformin nor rapamycin caused any significant differences in body weight
gain between treatment groups. After 6 weeks on diet, mice began metformin treatment in
the drinking water at doses of 250 and 50 mg/kg body weight per day or received a very low
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dose of rapamycin (2 nmol) alone or in combination with the low dose of metformin (50
mg/kg). Promotion with 6.8 nmol of TPA was also begun at this same time point and was
continued for the duration of the study (25 weeks). In all treatment groups, there was
greater inhibition in the DIO group in terms of tumor multiplicity (Figure 4-4B). There was
42% inhibition of papilloma development in the DIO, 2 nmol rapamycin + TPA group
compared to just 19% in this same treatment group in the control/overweight mice. The
DIO, 50 mg/kg metformin + TPA treatment group displayed 44% inhibition versus 34% in
the control/overweight group, and the combination group displayed 62% inhibition as
compared to 52% inhibition in the control/overweight group. Tumor multiplicity and percent
inhibition in each diet/treatment group are summarized in Figure 4-5. In terms of tumor
incidence, there were modest decreases with each treatment group as compared to the
DMBA-TPA control group as the 2 nmol rapamycin + TPA treatment group reached 84%
incidence, the 50 mg/kg metformin + TPA group reached 93% incidence and the 250 mg/kg
metformin + TPA group reached 83% incidence as compared to 100% incidence in the
DMBA-TPA control group (Figure 4-4C). In addition, there were differences in tumor latency
between the treatment groups and the DMBA-TPA control group. Time to 50% incidence
was 13-14 weeks in the single compound treatment groups (i.e. 250 mg/kg or 50 mg/kg met
+ TPA, 2 nmol rapamycin + TPA) compared to 8-9 weeks in the DMBA-TPA control group.
In addition, the combination treatment group did not reach 50% incidence until week 16
(Figure 4-4C).
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Figure 4-3
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Figure 4-3 Metformin and rapamycin did not significantly alter weight gain in mice on
control (overweight) or obesity inducing diets A) Weight gain throughout 30-week
period for mice receiving DIO, high fat diet (60 kcal % fat). Mice were weighed weekly for
duration of experiment. Differences in weight between treatment groups were not
significant. B) Weight gain throughout 30-week period for mice receiving control/overweight
diet (10 kcal% fat). Mice were weighed weekly for the duration of experiment. Differences in
weight between treatment groups were not significant. C) The differences between body
weights between the two diet groups were statistically significant (31.6 + 0.86 vs. 45.2 +
0.63, P < 0.05, Mann-Whitney U).
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Figure 4-4
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Figure 4-4 Metformin given in the drinking water is a potent inhibitor of skin tumor
promotion by TPA in obese mice. A) Female FVB/N mice 7-8 weeks of age were initiated
with 25 nmol of DMBA. Mice were then placed on the control diet (10 kcal % fat). After a 2
week period to equilibrate, mice were placed on the high fat diet (DIO, 60 kcal % fat). After
6 weeks on diet, mice were administered metformin via the drinking water, and promotion
began with 6.8 nmol of TPA. In experiments with combination treatments, 2 nmol of
rapamycin was applied topically 30 min prior to TPA. B) Differences in tumor multiplicity at
25 weeks between the 250 mg/kg metformin + TPA (--) or 50 mg/kg metformin + TPA (●)
and the DMBA-TPA control group (■) were statistically significant. In addition, differences in
tumor multiplicity between 2 nmol rapamycin + TPA (▲) or the combination group, 2 nmol
rapamycin, 50 mg/kg metformin + TPA (○) were statistically significant (*, P<0.05, MannWhitney U). C) Differences in tumor incidence at 25 weeks between 2 nmol rapamycin +
TPA (▲), 250 mg/kg metformin + TPA (--), or 2 nmol rapamycin, 50 mg/kg metformin +
TPA (○) and the DMBA-TPA control group (■), were statically significant (**, P<0.01,***,
P<0.001, 2-test).
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Figure 4-5

Figure 4-5 Summary of the effects of metformin and rapamycin on skin tumor
promotion in overweight and obese mice. Figure represents data collected at 27 weeks
of tumor promotion with 6.8 nmol of TPA after which papilloma response had reached a
plateau. Metformin, rapamycin and combination treatments appeared to be more highly
effective in the obese mice (60 kcal % fat).
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4.3 Metformin and rapamycin reduce skin tumor size in overweight and obese mice

In addition, the impact of diet and metformin or rapamycin treatment on tumor growth was
analyzed. As shown in Chapter 3, treatment with rapamycin to existing skin tumors led to
decreases in the size of pre-existing papillomas in mice of a normal weight, so a similar
effect on tumor growth with rapamycin and possibly metformin in the context of dietary
energy balance was expected. During week 23 of the two-stage study, a representative
subset of papillomas (approx. 25) from each treatment and diet group was measured to
determine average surface area. The DIO, high fat diet DMBA-TPA control group was
associated with an increase in tumor growth and overall tumor size as compared to the
DMBA/TPA, overweight/control group (tumor size of 30 + 3.2 mm2 for DIO vs 20 + 2.6 mm2
for control diet, P < 0.05, Mann-Whitney U) (Figure 4-6). In response to treatment with
either rapamycin or metformin, tumor size was reduced in both dietary groups. In addition,
the effect appeared to be additive with the combination treatment group. While there were
reductions in tumor size with each diet and treatment regimen, the effect was more
pronounced in the obese mice, with significant differences seen in all treatment groups. In
terms of the percent of reduction in tumor size, groups receiving 2 nmol rapamycin + TPA
displayed 46% reduction in tumor size in the DIO diet as compared to just 18% in the
control/overweight diet. In groups receiving 50 mg/kg metformin + TPA, the DIO group
displayed a 60% decrease in tumor size versus 43% decrease in the control/overweight diet
group. The combination treatment groups in both diet groups had similar percentages of
reductions in tumor growth (69% in DIO group vs. 67% in control/overweight group). This
data further shows the inhibitory effects of both rapamycin and metformin on skin tumor
promotion during dietary energy balance effects. Furthermore, this data also provides
evidence to suggest that each of these compounds may be more highly effective in an
obese state.
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Figure 4-6
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Figure 4-6 Metformin and rapamycin treatment reduced the size of skin tumors in
both overweight and obese mice. Impact of diet and metformin and/or rapamycin
treatment on tumor growth in mice. A) Average surface area of a random subset of
papillomas taken at week 23 during two-stage study from overweight mice. Graphs
represent the average surface area + SEM. The combination treatment group’s papilloma
size (2 nmol rapamycin, 50 mg/kg metformin + TPA) was significantly smaller than the
DMBA-TPA control group papilloma size (***, P>0.001, Kruskal Wallis Test). B) Average
surface area of a random subset of papillomas taken at week 23 during two-stage study
from obese mice. Graph represents the average surface area + SEM. Differences in tumor
size in all treatment groups were statistically significant from the DMBA-TPA control group.
(*,P >0.05, ***,P >0.001, Kruskal Wallis Test).
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Chapter 5: Mechanisms Associated with the Inhibitory Effects of Rapamycin and
Metformin on Skin Tumor Promotion by TPA

After obtaining promising, highly reproducible skin tumor data from two-stage skin
carcinogenesis experiments demonstrating the inhibitory effects of both rapamycin and
metformin on skin tumor promotion by TPA, the underlying mechanisms behind the efficacy
of these chemopreventive agents were explored. The two-stage skin carcinogenesis model
has proven very useful in defining various stages of epithelial carcinogenesis as well as
biochemical events that are associated with each stage (126).Thus a number of short term
markers are available that enable us to study the underlying molecular mechanisms of
various modifying factors (i.e. compounds, dietary energy balance manipulation) on tumor
response. For instance, the tumor promotion stage is associated with the selective clonal
expansion of initiated cells. Furthermore, this stage is characterized by heightened and
sustained hyperplasia prior to the development of small exophytic skin tumors referred to as
papillomas. Previous, published data has also well characterized the expression of many
proteins during both the promotion and progression phases of skin tumorigenesis some of
which include γ-glutamyltransferase, keratin-8, keratin-1, E-cadherin and loricrin (101). In
addition, tumor promoter activation of several PKC isoforms is critical for the induction of
proliferation and inflammation. Particularly, their activation results in the secretion of several
pro-inflammatory molecules from keratinocytes which result in further recruitment of
macrophages, leukocytes, and lymphocytes involved in the innate immune response into
the dermal compartment. These activated cells are then able to further promote cellular
proliferation, angiogenesis, and suppression of adaptive immunity through secretion of
various cytokines, chemokines and growth factors thus facilitating skin tumor promotion
(127).
Furthermore, in the context of dietary energy balance, more recent data has
emerged elucidating possible mechanisms through which CR or DIO may affect the
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carcinogenic process. In this section, mechanisms associated with the differential effects of
these compounds or agents on dietary energy balance manipulation during skin tumor
promotion are studied.

5-1 Rapamycin inhibits TPA-induced epidermal hyperproliferation
Sustained cellular proliferation in the epidermis leads to chronic hyperplasia which is a
hallmark of skin tumor promotion. In addition, short term markers of this including BrdU
incorporation (labeling index) and epidermal thickness have become reliable predicators of
tumor promoting capabilities of compounds as well as the effectiveness of inhibitor
compounds (126). After the dramatic effects of rapamycin on skin tumor promotion by TPA
were witnessed, the effect of rapamycin on TPA-induced epidermal hyperproliferation and
hyperplasia in mice of a normal weight was explored.

For these experiments, groups of female FVB/N mice 7-8 weeks of age were treated
topically with acetone (vehicle) or various doses of rapamycin (5-200 nmol) followed
30 min later by 6.8 nmol of TPA. This treatment regimen was continued twiceweekly for two weeks (i.e. 4 treatments total), and mice were sacrificed 48 hours
after the final treatment. After sacrifice, the skin was removed and processed for
histological examination. Whole skin sections were evaluated for epidermal
hyperplasia (as measured by epidermal thickness) and epidermal LI (as measured
by BrdU incorporation). Figure 5-1A shows representative H&E and BrdU stained
sections of dorsal skin after multiple treatments with either acetone, 6.8 nmol TPA,
or 200 nmol of rapamycin followed by 6.8 nmol of TPA. Visual inspection of the
sections revealed that rapamycin significantly reduced epidermal hyperplasia as
well as LI when applied 30 minutes prior to TPA application. Quantitative analyses
of the effect of rapamycin on TPA induced epidermal hyperplasia and LI are
summarized in Figures 5-1B and 5-1C, respectively. All doses of rapamycin used
(200, 100, 50, 20 and 5 nmol) produced statistically significant reductions in
epidermal thickness and labeling index (LI) induced by TPA treatment (*, P<0.05,
Mann Whitney U). These data demonstrate that rapamycin effectively blocked TPAinduced epidermal hyperproliferation and that this effect may explain its ability, at
least in part, to inhibit skin tumor promotion by TPA. [Reprinted from (114)]
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Figure 5-1

C

Figure 5-1 Rapamycin inhibits TPA-induced epidermal hyperplasia in a dosedependent manner A) Representative sections of H&E and BrdU stains of dorsal skin
collected from female FVB mice after multiple treatments with either acetone, 6.8 nmol of
TPA, or 200 nmol (rapa) followed by 6.8 nmol of TPA (twice a week for 2 weeks). B)
Quantitative evaluation of the effects of rapamycin on TPA-induced epidermal hyperplasia
(epidermal thickness) C) Quantitative evaluation of the effects of rapamycin on TPA –
induced epidermal hyperproliferation (labeling index: LI). Values represent the mean +
SEM. (*, P< 0.05; Mann-Whitney U). [Reprinted from (114)]
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5-2 Rapamycin reduces TPA-induced inflammation in mouse skin
Another short term marker and chronic feature of skin tumor promotion is inflammatory cell
infiltration (101, 127). Hence, the effects of rapamycin on TPA-induced inflammation were
studied to provide a potential mechanism by which rapamycin could be exerting its potent
inhibitory effects in addition to inhibition of mTORC1 in mice of a normal weight.

During the course of analyzing skin sections from rapamycin-treated mice, a
significant decrease in dermal inflammation and dermal inflammatory cell numbers
was observed. Therefore, the effect of topical treatments of rapamycin prior to TPA
on dermal inflammatory cell infiltration was further examined. For these
experiments, groups of female FVB/N mice, 7 to 8 weeks of age, were treated
topically with acetone (vehicle) or various doses of rapamycin (5–200 nmol) followed
30 minutes later by 6.8 nmol of TPA. This treatment regimen was continued twice
weekly for 2 weeks, and mice were sacrificed 48 hours after the final treatment for
histochemical and immunohistochemical analysis of various inflammatory cells.
Whole skin sections were processed and stained for the following markers including
CD3 (T cells), S100A9 (macrophages), LY6G (neutrophils), and toluidine blue (mast
cells). As noted above, visual inspection of skin sections revealed that rapamycin
dramatically reduced infiltration of all 4 types of inflammatory cells as seen in Figure
5-2 for the 200 nmol dose of rapamycin (A–D, respectively). Quantitative analyses
of each cell type at 2 different doses of rapamycin (200 and 5 nmol) are shown
in Figure 5-3. Rapamycin at both doses presented produced statistically significant
reductions in the number of all inflammatory cell types examined (*, P < 0.05;
Mann–Whitney U). [Reprinted from (114)]
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Figure 5-2
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Figure 5-2 Visual representation of the inhibition of TPA-induced dermal
inflammation by rapamycin A) Representative sections of CD3-stained (T cells) dorsal
skin sections collected after multiple treatments of acetone, 6.8 nmol of TPA, or 200 nmol
rapamycin (rapa) + TPA. B) Representative sections of S100A9-stained (macrophages)
dorsal skin sections collected after multiple treatments of acetone, 6.8 nmol of TPA, or 200
nmol rapamycin (rapa) + TPA. C) Representative sections of LY6G-stained (neutrophils)
dorsal skin sections collected after multiple treatments of acetone, 6.8 nmol of TPA, or 200
nmol rapamycin (rapa) + TPA. D) Representative sections of toluidine blue-stained (mast
cells) dorsal skin sections collected after multiple treatments of acetone, 6.8 nmol of TPA,
or 200 nmol rapamycin (rapa) + TPA. [Reprinted from (114)]
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Figure 5-3

Figure 5-3 Quantitative analysis of the effect of rapamycin on TPA-induced dermal
inflammation A) Average number of positive cells per 24 fields (200 µm2) for CD3-stained
sections in acetone, 6.8 nmol TPA, 200 nmol rapamycin + TPA, and 5 nmol rapamycin +
TPA treated skins. B) Average number of positive cells per 24 fields (200 µm2) for S100A9stained sections in acetone, 6.8 nmol TPA, 200 nmol rapamycin + TPA, and 5 nmol
rapamycin + TPA treated skins. C) Average number of positive cells per 24 fields (200 µm2)
for LY6G-stained sections in acetone, 6.8 nmol TPA, 200 nmol rapamycin + TPA, and 5
nmol rapamycin + TPA treated skins. D) Average number of positive cells per 24 fields (200
µm2) for Toluidine blue-stained sections in acetone, 6.8 nmol TPA, 200 nmol rapamycin +
TPA, and 5 nmol rapamycin + TPA treated skins. Values represent the mean + SEM. (*, P<
0.05; Mann-Whitney U). [Reprinted from (114)]
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Because there were dramatic reductions in dermal inflammatory cell infiltration, the
anti-inflammatory effects of rapamycin during skin tumor promotion were further explored.
The enzyme cyclooxygenase 2 (COX-2) is a critical mediator of inflammation and serves as
the catalyst for the rate limiting step in the conversion of arachidonic acid into
prostaglandins (128). It is inducibly expressed in many different tissues by, but not limited
to, tumor promoting agents. COX-2 is also induced by various growth factors, oncogenes
and pro-inflammatory cytokines (129). As shown in Figure 5-4, TPA applied directly to the
skin potently induced COX-2 expression at 6 h post treatment in mouse epidermis.
Previous data also support this activation in mouse skin after TPA is topically applied (130).

Figure 5-4
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Figure 5-4 Rapamycin inhibits TPA-induced expression of COX-2 in the epidermis.
Pooled protein lysates were prepared from the epidermal scrapings of female FVB/N mice
undergoing a multiple treatment regimen of acetone, 6.8 nmol of TPA, 200 nmol rapamycin
(rapa), or various doses of rapamycin (2-200 nmol) prior to 6.8 nmol TPA. Western blot
analyses were then conducted to determine the effect of topical rapamycin treatment on
inflammatory signaling pathways in the epidermis.
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Consistent with the observed reduction in dermal inflammatory cells, topical rapamycin
treatment also produced potent decreases in epidermal COX-2 expression after a multiple
treatment protocol in which female FVB/N mice 7-8 weeks of ages received treatment with
either acetone, 200 nmol rapamycin, 6.8 nmol of TPA, or various doses of rapamycin (2200 nmol) prior to treatment with 6.8 nmol of TPA (Figure 5-4).
Eukaryotic transcription factor NFҡB critically regulates the expression of many
genes including COX-2, as the cox-2 promoter contains an NFҡB binding site. Prior to
activation, NFҡB dimers are retained in the cytoplasm by binding to the members of the IҡB
(IKK) inhibitory complex. Cellular stimulation of IKK stimulates rapid degradation via
polyubiquitination of this complex allowing for the freed NFҡB dimers to translocate to the
nucleus to coordinate the transcription of hundreds of target genes including COX-2 (131).
While the upstream signaling cascade proceeding NFҡB activation is quite complex, there
is evidence that kinases involved include mitogen-activated protein (MAP) kinases, such as
p38, c-Jun and ERK (132). Additional data from our lab has also found that topical
application of rapamycin at a dose of 50 nmol decreased TPA-induced activation of NFҡB
subunit p65 or RelA as indicated by a decrease in phosphorylation of this protein at Ser536
in the epidermis (Data not shown). In addition, in this experiment, there was attenuation of
signaling through p38 (Figure 5-4). On a molecular basis, this preliminary signaling data
suggest that one facet of rapamycin’s anti-tumor action may be through inhibition of TPAinduced inflammation through decreases in expression of COX-2. Specifically, this may
occur through suppression of signaling through p38 and subsequent inhibition of NFҡB.
Further experiments are necessary to confirm the exact mechanism by which rapamycin
exerts these potent anti-inflammatory effects.
Overall, these data provide another possible mechanism by which rapamycin might
exert its potent inhibition of skin tumor promotion. At the start of this project, the primary
hypothesis comprised a situation in which rapamycin exerted its anti-tumor effects primarily
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through inhibition of mTORC1 and subsequent downstream signaling to which included
many cell cycle regulatory proteins. However, this data provides an interesting scenario by
which rapamycin may exhibit dual inhibitory effects. There are however conflicting results in
terms of the effect of rapamycin on inflammation in cancer. Previous studies from Granville
and colleagues reported that there were no significant changes in macrophage content of
skin tumors from mice collected after treatment with rapamycin compared to tumors treated
with the control (vehicle treated) (81). Amornphimoltham et al. also reported no change in
T-cell or macrophage content in tumors after rapamycin treatment (80). However, in both of
these studies, the route of administration of rapamycin was different (IP injection), and each
study evaluated the effect of rapamycin on inflammation in pre-existing tumors. In our
protocol, rapamycin’s effect on skin tumor promotion was evaluated via a short term
mechanistic study which represents the early phases of skin tumor promotion before skin
tumors developed. Therefore, the current data suggest that the anti-inflammatory effects of
rapamycin may have been exerted earlier in the skin carcinogenesis process during the first
few weeks of skin tumor promotion thus contributing to its anti-tumorigenic effects.

5-3 Rapamycin inhibits TPA-induced activation of mTORC1 and downstream
signaling in mouse epidermis
To further explore the potential mechanisms by which rapamycin inhibited TPAinduced epidermal hyperproliferation and skin tumor promotion, experiments were
conducted to evaluate changes in epidermal Akt and mTOR signaling pathways. For
these experiments, female FVB/N mice, 7 to 8 weeks of age, were treated topically
with either acetone or various doses of rapamycin (5–1,000 nmol) 30 minutes prior
to treatment with 6.8 nmol of TPA twice weekly for 2 weeks (total of 4 treatments).
Note that a higher dose of rapamycin (1,000 nmol) was used in initial Western blot
experiments (Figure 5-5A). However, in subsequent experiments, it was not used,
as doses of 50, 100, and 200 nmol rapamycin completely inhibited skin tumor
promotion by TPA. Mice were sacrificed 6 hours after final treatment and epidermal
protein lysates were prepared for Western blot analyses of Akt, mTOR, and several
mTORC1 downstream effector molecules. Topical application of TPA using this
protocol led to phosphorylation of mTOR (Ser2448), and downstream effectors of
mTORC1 including p70S6K (Thr389), p4E-BP1 (Thr37/46 and Ser65), and pS6
ribosomal (Ser240/244); (Figure 5-5A and B) as well as phosphorylation of Akt
(Thr308 and Ser473); Figure 5-5C and D as expected on the basis of previous studies
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(106, 113). Although the phosphorylation of mTOR (Ser2448) was reduced somewhat
at several doses of rapamycin, the most dramatic effects were seen on
phosphorylation of p70S6K and S6 ribosomal protein (Figure 5-5A and B). In this
regard, phosphorylation of the mTORC1 downstream effectors p70S6K (Thr389) and
p-S6 ribosomal protein (Ser240/244) was decreased in the rapamycin-treated groups
in a dose-dependent manner. In addition, at the 1,000-nmol dose, p4E-BP1
(Thr37/46 and Ser65) was decreased as compared with the TPA-treated group.
Rapamycin given at a dose of 200 nmol in this multiple treatment regimen appeared
to increase Akt phosphorylation at Ser473 as well as increase phosphorylation at the
Thr308 site (again see Figure 5-5C and D). None of the other doses of rapamycin
appeared to affect Akt phosphorylation at either site. Figure 5-5B and D show the
quantitation of the Western blot analyses shown in Figure 5-5A and C, respectively.
Similar results were obtained in a separate, independent experiment. The Western
blot analyses shown in Figure 5-5A and C are representative of both experiments.
The quantitation shown in Figure 5-5B and D represent an average from both of
these experiments. Collectively, these data suggest that treatment with rapamycin
led to inhibition of TPA-induced mTORC1 downstream signaling, particularly
through the p70S6K and S6 ribosomal protein pathway. Furthermore, at higher
doses (≥200 nmol per mouse), rapamycin also appeared to increase Akt
phosphorylation at Thr308. [Reprinted from (114)]
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Figure 5-5

Figure 5-5 Rapamycin inhibits TPA-induced signaling through mTORC1. Effect of
rapamycin on TPA-induced mTOR signaling in mouse epidermis using a multiple treatment
protocol. Pooled protein lysates were prepared from the epidermal scrapings of FVB/N mice
undergoing a multiple treatment regimen of acetone, 6.8 nmol TPA, 200 and 1000 nmol
rapamycin (rapa), or various doses of rapamycin (5-1000 nmol) prior to 6.8 nmol TPA.
Western blot analyses were then conducted to examine activation of Akt and mTOR and
downstream targets. A) Western blot analysis of mTOR and downstream signaling
molecules. B) Quantification of Western blot analyses in A. C) Western blot analysis of Akt
phosphorylation status. D) Quantification of Western blot analysis in C. These experiments
were repeated with nearly identical results. Note that the quantitation shown in B and D
represent an average of the two experiments, whereas the Western blot analysis in A and C
are from a single representative experiment. [Reprinted from (114)]
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In addition, even after a single topical application of rapamycin to the skin,
rapamycin potently inhibited signaling through mTORC1 (data not shown). Furthermore,
there was inhibition of mTORC1 and downstream signaling through disruption of mTOR
and raptor after topical administration of rapamycin prior to TPA treatment. As shown in
figure 5-6, multiple treatments with rapamycin at doses of 1000 and 20 nmol effectively
disrupted interactions between raptor and mTOR. This effect also appeared to be dose
dependent.
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Figure 5-6 Multiple treatments with rapamycin at higher doses prevent mTOR
complex I formation. Female FVB/N mice were treated topically with either acetone,
rapamycin, 6.8 nmol TPA or 1000 nmol or 20 nmol of rapamycin prior to TPA treatment.
Epidermal lysates were prepared as previously described. Panel shows coimmunoprecipitation with raptor and subsequent western blot analyses of mTOR and
raptor.
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Overall, this data is consistent with previous published reports that attribute the antitumor effects of rapamycin to its ability to reduce signaling through mTORC1 and further
downstream as assessed by levels of pS6 (80). As demonstrated in Figure 5-5A and B,
rapamycin applied topically 30 min prior to treatment with 6.8 nmol of TPA, inhibits TPAinduced mTORC1 activation in the epidermis as evidenced by decreased phosphorylation
of mTOR (Ser2448) and its downstream targets p70S6K (Thr389) and pS6 ribosomal protein
(Ser240/244). In addition, another downstream target of mTORC1, translation repressor 4EBP1 was evaluated. Interestingly, rapamycin only appeared to effect phosphorylation of
4E-BP1 at the highest dose of rapamycin tested (1000 nmol). At lower doses used, there
appeared to be much less inhibition of this protein. As discussed in the Introduction chapter,
4E-BP1, when unphosphorylated, binds to initiation factor eIF4E, and inhibits capdependent translation. Our observation is consistent with previous reports that show full
inhibition of p70S6K and pS6, but only partial inhibition of 4E-BP1 after rapamycin
treatment (133, 134). However, it should be noted that the phosphorylation of 4E-BP1 is
quite complex and requires phosphorylation from various other kinases for release from
eIF4E to inhibit translational activation. Previously published data showed that
phosphorylation at the Thr37 and Thr46 sites of 4E-BP1 by mTORC1 did not eliminate its
binding to eIF4E and that other kinases are required for eIF4E’s release and subsequent
translation activation (135). In summary, the current data indicate that the inhibitory effects
of rapamycin on mTORC1 signaling appear to be primarily mediated through downstream
targets p70S6K and pS6, and effects through downstream target 4E-BP1 appear to be less
important in terms of inhibition of skin tumor promotion (114).
In terms of Akt status in the epidermis, interestingly rapamycin at a dose of 200
nmol increased activation of Akt as evaluated by phosphorylation at Thr308. This activation
was not apparent at the lower doses of rapamycin used (100, 50, 20 and 5 nmol) as shown
in Figure 5-5C and D. The increase in activation in this multiple treatment regimen was
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attributed to a partial inhibition of the mTORC1-dependent negative feedback loop in which
p70S6K and pS6 negatively regulate insulin signaling through phosphorylation of IRS-1
causing subsequent attenuation of signaling through PI3K/Akt. This conclusion is also
supported by previous published data that have shown an increase in Akt activity after
treatment with mTOR inhibitors due to reductions in feedback inhibition of the PI3K/Akt
pathway (121). In addition, phosphorylation of Akt at Ser473 at a dose of 200 nmol may have
also been slightly increased (Figure 5-5C and D). However, further experiments in our lab
have demonstrated decreased phosphorylation of PRAS40 at Thr246 which is the Aktspecific phosphorylation site when rapamycin was applied topically to the skin prior to TPA
(data not shown). Consonant with this observation, Sarbassov and colleagues (76) reported
that rapamycin inhibited mTORC2 assembly after subsequent Akt activity in vitro after
prolonged treatment. Further investigations will be necessary to determine whether the
mTORC2 complex is disrupted in response to rapamycin at higher dose, multiple treatment
regimens. Nonetheless, lower doses of rapamycin (i.e. 100, 50, 20 and 5 nmol) effectively
inhibited epidermal mTORC1 signaling and complex formation without any effects on
phosphorylation status of Akt at either Ser473 or Thr308 and this inhibition appears to be a
primary mechanism and biochemical altercation associated with inhibition of murine skin
tumor promotion (114).
These initial finding demonstrate the importance of Akt downstream substrate
mTORC1 in mediating the effects of rapamycin on skin tumor promotion by TPA via
reduction of signaling through p70S6K and pS6 as well as a through reduced TPA-induced
inflammation. Next, a possible mechanism through which rapamycin exerts its potent antitumor effects via induction of autophagy was explored. It is possible that some of the
chemopreventive actions of rapamycin demonstrated in our model are a concerted effort
between a reduction in protein synthesis, a reduction in inflammation as well as increases
in pro-autophagic pathways. Most pro-autophagic events including initiation and nucleation
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converge on the mammalian Target of Rapamycin (mTOR). Activation of these pathways
may provide a less hostile microenvironment via reductions in damaged proteins and
organelles and subsequent reductions in overall inflammation.
Preliminary data gathered showed that topical application of rapamycin induced
pro-autophagic or autophagic proteins in mouse epidermis after TPA treatment. Initial
results have demonstrated increases in specific protein markers that have been validated
as visual markers for autophagosome formation including LC3B II as well as autophagic
initiator beclin-1. Autophagy Marker Light Chain 3 (LC3B) is cleaved at the C-terminal end
by Atg5 into a cytoplasmic form of LC3B-I. If autophagy is present, then cytosolic LC3B-I is
cleaved into LC3B-II and is then recruited to the autophagosomal membrane (58). Beclin-1
is involved in the initiation step of autophagy and acts as a platform for binding activators
such as UVRAG or repressors such as Bcl-2 depending on external signaling and nutrient
stimuli, rather than possessing its own enzymatic activity (136).
Consistent with previous data that demonstrated PKC activation to downregulate
autophagy (137), topical treatment with 6.8 nmol of TPA down-regulated beclin-1 and
LC3B-II (Figure 5-7).Treatment with rapamycin at various doses (1000 nmol, 100 nmol and
20 nmol) prior to TPA treatment reversed the reduction in autophagic markers seen with
TPA treatment alone in mouse epidermis. Expression of LC3B-II and beclin-1 was
increased in rapamycin treated groups compared to the TPA only treated group which
primarily expressed the uncleaved form, LC3B-I (Figure 5-7). Ongoing studies in the lab are
also evaluating the effect of rapamycin treatment on autophagy regulators directly
downstream of mTORC1, such as ULK1. Preliminary Western blot analyses showed
phosphorylation of ULK1 at Ser757, which is the mTORC1 phosphorylation site, after TPA
application to the skin (Figure 5-7). Phosphorylation of ULK1 by mTORC1 at this site
inactivates the ULK1/FIP200/ATG13 complex, inhibiting its release from mTOR and raptor
thus preventing the association between AMPK and ULK1 and the induction of autophagy
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(63). However, in skins treated with rapamycin at doses of 100, 20 and 2 nmol prior to
treatment with 6.8 nmol of TPA, phosphorylation of ULK1 at this site was abolished (Figure
5-7). Interestingly, the highest dose of rapamycin used caused an increase in
phosphorylation at this site comparable to the increases in phosphorylation seen with TPA.
We hypothesized that this increase could be due to a novel negative feedback loop
involving mTOR, raptor and ULK1 described by Dunlop et al. They provided evidence that
ULK1 promotes phosphorylation of raptor at multiple sites thus hindering substrate binding
to this complex causing inhibition of mTORC1. Upon overexpression, ULK1 promoted
increases in mTORC1 kinase activity through the autophosphorylation site (Ser2481)
despite continued inhibition of mTORC1 mediated phosphorylation of p70S6K and 4EBP1(138). It’s probable that higher doses of rapamycin may affect ULK1’s interactions with
raptor thus altering mTORC1 activity.
A summary of our findings on the impact of rapamycin on Akt/mTOR
phosphorylation and downstream effectors following rapamycin treatment in mouse
epidermis can be found in Figure 5-8.
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Figure 5-7
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Figure 5-7 Effect of rapamycin on the induction of autophagy in the epidermis using
a multiple treatment protocol. Pooled protein lysates were prepared from the epidermal
scrapings of FVB/N mice undergoing a multiple topical treatment regimen of acetone, 6.8
nmol TPA, 1000 nmol or 200nmol of rapamycin, or various other doses of rapamycin (201000 nmol) prior to 6.8 nmol of TPA. Western blot analyses were conducted to examine the
activation of autophagic markers LC3B, beclin-1 and ULK1.
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Figure 5-8
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Figure 5-8 Summary of the impact of rapamycin treatment on Akt/mTOR
phosphorylation in mouse epidermis following TPA treatment. Impact of low dose
rapamycin treatment represented in blue. Impact of high dose rapamycin treatment
represented in red. High doses of rapamycin used (200 and 1000 nmol) affected mTORC1dependent negative feedback inhibition of PI3K/Akt as well as inhibited mTORC1.
Rapamycin at low doses (5-100 nmol) that inhibited skin tumor promotion primarily affected
downstream targets p70S6K, pS6 and ULK1.
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5-4 Metformin attenuates TPA-induced epidermal hyperproliferation

After obtaining exciting results from two-stage skin carcinogenesis experiments
demonstrating anti-carcinogenic effects of metformin during the tumor promotion stage
when administered via the drinking water, the potential mechanisms by which this antidiabetic drug and apparent anti-neoplastic agent was exerting these effects was examined.
First, to further examine the ability of metformin to reduce proliferation in the epidermis,
short term markers of skin tumor promotion, hyperproliferation (BrdU incorporation) and
hyperplasia (epidermal thickness) were evaluated after TPA treatment. For these
experiments, groups of normal weight female FVB/N mice 7 to 8 weeks of age were
topically treated with either acetone or 6.8 nmol of TPA twice a week for two weeks with or
without the addition of metformin in the drinking water at doses of 350, 250 or 50 mg/kg
body weight per day for the duration of the study. Mice were sacrificed 48 hours after the
final acetone or TPA treatment, and skin sections were removed for histological
examination. Figure 5-9A displays representative H&E and BrdU stained skin sections from
the acetone, TPA, and 250 mg/kg metformin + TPA treatment group. Visual inspection
revealed modest decreases in both epidermal thickness and labeling index in response to
metformin administration in the drinking water. Upon quantitative evaluation as shown in
Figure 5-9B the range of doses of metformin used significantly reduced each parameter
measured compared to the TPA control group. The reductions also appeared to be dosedependent (*, P<0.05, Mann-Whitney U). Overall, this data shows metformin’s ability to
inhibit, a least partially, TPA-induced hyperproliferation. This may help explain how it
inhibits skin tumor promotion.
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Figure 5-9
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Figure 5-9 Metformin inhibits TPA-induced hyperplasia and hyperproliferation. A)
Representative sections of H&E and BrdU stains of dorsal skin collected from female
FVB/N mice after multiple treatments with either acetone, 6.8 nmol of TPA twice a week for
two weeks with or without metformin in the drinking water at the representative dose of 250
mg/kg body weight per day. B) Quantitative evaluation of the effects of metformin on TPAinduced epidermal hyperplasia (epidermal thickness and labeling index: LI). Values
represent the mean + SEM. (*, P< 0.05; Mann-Whitney U).
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5-5 Metformin activates epidermal AMPK and attenuates TPA-induced signaling
through mTORC1

As discussed in the Introduction, metformin acts by inhibiting oxidative phosphorylation thus
increasing intracellular levels of AMP and subsequently activating the LKB1/AMPK pathway
(139, 140). This action, when occurring in the liver, impairs gluconeogenesis thus lowering
glucose production and subsequent circulating insulin levels. Current data has revealed that
this activation of AMPK in neoplastic cells can result in decreased cellular proliferation
(141). Thus, the anticancer effects of this drug may be a result of either an indirect insulin
lowering effect due to activation of AMPK in the liver, and/or a direct effect by activation of
AMPK and further alterations in cell signaling and gene expression in transformed cells.
Distinguishing between direct and indirect mechanisms behind the anticancer effects of
metformin is important, as most epidemiological data show metformin’s anticancer effects in
type II diabetes populations which tend to be obese and display chronic hyperinsulinemia.
Our initial experiments explored the baseline effects (independent of diet) of short term
administration of metformin in the drinking water (two weeks) on AMPK activation and
subsequent signaling through mTORC1 and further downstream in female FVB/N mice on a
regular chow diet in response to treatment with tumor promoter, TPA. During this period,
mice received topical treatments with either acetone (vehicle) or 6.8 nmol of TPA with or
without metformin in the drinking water at doses of 250 and 50 mg/kg body weight per day.
Mice were sacrificed 6 h after the final acetone or TPA treatment, and epidermal protein
lysates were prepared. Activation of AMPK has been shown to inhibit signaling through
mTORC1, therefore it was hypothesized that metformin inhibits the growth of skin tumors
via activation of AMPK and a subsequent decrease in signaling through mTORC1/p70S6K
resulting in limitations in protein synthesis. Western blot analyses showed abundant
activation of AMPK in the epidermis in groups receiving both doses of metformin as
compared to the TPA-control treated group (Figure 5-10A).
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As previously shown, topical TPA treatment to the skin resulted in potent activation
of mTORC1 as shown though increases in phosphorylation of p70S6KT389, pS6rS240/244,
pS6rS235/236, and p4E-BP1S37/46, as well as degradation of mTORC1 downstream target,
PDCD4. In treatment groups receiving metformin, there was a dose-dependent reduction in
p70S6K T389 as well as pS6rS235/236 (Figure 5-10A and B). In addition, translational repressor
PDCD4 was partially protected from degradation at the higher dose of metformin used (250
mg/kg). In this short term administration protocol, metformin had no apparent effect on
mTORC1 mediated phosphorylation of 4E-BP1. Figure 5-10B shows the quantification of
these blots with graphs displaying the mean and SEM from three independent experiments.
It should be noted that while there was a dose-dependent response, only the highest dose
used (250 mg/kg) had statistically significant differences in protein activation from the TPAcontrol treated group. Graphs without error bars represent the average from two
independent experiments.
The data thus far supports an AMPK dependent mechanism for the inhibition of skin
tumor development in the two-stage skin carcinogenesis model. It is well established that
one of the primary pharmacological mechanisms of action of metformin is activation of
AMPK (142). Activation of the LKB1/AMPK pathway activates a host of downstream
effectors that modulate cellular growth and metabolism and helps regulate energy balance
in the cell during times of stress (87). In short term mechanistic studies, metformin partially
inhibited signaling through mTORC1. Furthermore, this inhibition was confirmed to be
associated with AMPK activation as evidenced by increases in phosphorylation of AMPK at
activation site Thr172 in the presence of metformin. Another downstream target of AMPK
that might be of interest to explore is Acetyl CoA carboxylase. Acetyl CoA carboxylase,
when activated causes the carboxylation of acetyl-CoA to produce malonyl-CoA, which is
the rate limiting step in de novo fatty acid synthesis (99). This may also represent another
downstream mechanism by which metformin exhibits anti-neoplastic effects, as many
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human cancers have been associated with fatty acid synthase (FASN) increases (143).
Further work will be necessary to explore these downstream signaling pathways in more
detail.
It should also be noted that there is additional evidence that metformin might
mediate its anti-cancer effects independently of LKB1 and AMPK. Kalender and colleagues
demonstrated metformin to inhibit signaling through mTORC1 independent of the
LKB1/AMPK axis by inhibiting Rag GTPase activation of mTOR (144). In addition,
metformin induced cell cycle arrest through REDD1 mediated inhibition of mTOR in
prostate cancer cell lines (145). Furthermore, the ability of metformin to inhibit
gluconeogenesis in the liver was not impaired in the absence of LKB1 and AMPK and
instead was initiated in response to flux in energy levels (146). Despite these interesting
observations, AMPK activation and subsequent mTORC1 inhibition remain the primary
proposed mechanism by which metformin exerts antineoplastic effects.
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Figure 5-10
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Figure 5-10 Metformin activates epidermal AMPK and attenuates TPA-induced
activation of mTOR and downstream targets. Pooled protein lysates were prepared from
the epidermal scrapings of FVB/N mice undergoing a multiple treatment regimen of either
acetone, 6.8 nmol of TPA with or without the addition of metformin in the drinking water at
doses of 250 and 50 mg/kg body weight per day. Western blot analyses were conducted to
examine activation of AMPK, mTORC1 and downstream targets. A) Western blot analyses
of AMPK and mTORC1 substrates. B) Quantification of Western blot analysis in A. Graphs
with error bars represent quantitation from three independent experiments (*, P<0.05,
Mann-Whitney U).

In preliminary experiments, the effects of low dose combinations of metformin and
rapamycin on epidermal mTORC1 signaling were explored to further characterize the
mechanisms of the additive effect of these two compounds that were witnessed in the twostage skin carcinogenesis protocol. As shown in Chapter 4, a combination of 50 mg/kg
body weight per day of metformin administered via the drinking water accompanied by
topical treatment with 2 nmol of rapamycin prior to promotion with 6.8 nmol of TPA was
sufficient in both overweight and obese mice to cause statistically significant reductions in
tumor development as compared to either compound alone. An additive effect was also
observed through the reduction of phosphorylation of p70S6K (Thr389) in the combination
group compared to either single agent alone in mouse epidermis. There was also dramatic
inhibition of the degradation of translational repressor PDCD4 in the combination treatment
group. (Figure 5-11).
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Figure 5-11

A

B

Figure 5-11 Combination treatments of metformin and rapamycin are more effective
than either agent alone at inhibiting TPA-induced mTORC1 signaling in the
epidermis. Pooled protein lysates were prepared from the epidermal scrapings of FVB/ N
mice undergoing a multiple topical treatment regimen of acetone, 6.8 nmol TPA, 2 nmol of
rapamycin or 50 mg/kg metformin, or these treatments alone or in combination prior to 6.8
nmol of TPA. A) Western blot analyses from a single representative experiment B)
Quantitation from western blots in A
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5-6 Effect of metformin on body weight, serum hormones, and glucose tolerance
As previously shown in Chapter 4, dietary intervention via administration of either the 10
kcal % fat, overweight/control diet or the 60 kcal % fat, DIO diet generated two different
weight phenotypes. In the last few weeks of the tumor study, after which mice had been on
diet for 30 weeks, the mean body weight of the DIO diet group was 45.2 + 0.63 g and the
mean body weight of the overweight/control diet group was 31.6 + 0.86, and differences
were statistically significant (*, P< 0.05, Figure 5-12D). As expected, there were also altered
levels of energy balance-related hormones in the overweight mice in the DMBA/TPA control
group as compared to the DIO mice in the DMBA/TPA control group as fasting insulin levels
on average in the DIO group were approximately 7-fold higher than the overweight control
group (P< 0.05; Figure 5-12A). Serum leptin levels were approximately 20-fold higher in the
DIO DMBA/TPA control group as compared to the overweight DMBA/TPA control group
(P<0.05; Figure 5-12B). However, differences in serum adiponectin levels were not
statistically significant in these two groups (Figure 5-12C). To determine whether or not
metformin exerts its anti-tumor effects in the two-stage model through indirect insulin
lowering effects or decreases in various other serum adipokines, serum hormones in the
metformin treated mice were evaluated. Metformin at a dose of 50 mg/kg body weight per
day in the drinking water reduced the elevated levels in insulin in the DIO, hyperinsulinemic
mice but had no effect on the insulin levels of mice receiving the overweight control diet
(DIO DMBA-TPA control: 4,828.9 + 1128.3 pg/ml versus DIO 50 mg/kg MET + TPA:
1,914.7 + 338.8 pg/ml; *, P< 0.05, Mann-Whitney U) (Figure 5-12A). In addition, adiponectin
levels were modestly higher in the DIO 50 mg/kg MET +TPA group compared to the DIO
DMBA-TPA control group, but there were no differences between the metformin and
DMBA-TPA treated groups in the overweight/control diet groups (DIO DMBA-TPA control:
6272.9 + 783.2 pg/ml versus DIO 50 mg/kg MET + TPA: 8,812.9 + 1018.4 pg/ml; *, P<
0.05, Mann-Whitney U) (Figure 5-12C). The addition of metformin in the drinking water had
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no apparent effect on circulating serum leptin levels (Figure 5-12B). This data is consistent
with previous published data that showed that while there were statistically significant
increases in leptin levels in mice receiving a high-energy diet vs the control diet, metformin
had no significant effects on leptin levels in either diet group (139)
Our findings show that metformin reduced increases in circulating insulin levels in
obese mice consuming the high fat diet (60 kcal % fat) suggesting that the antitumor effects
of metformin in the skin carcinogenesis model may partially occur via LKB1/AMPK
activation in the liver and subsequent inhibition of gluconeogenesis. While there was
reduced signaling in the epidermis through mTORC1 via AMPK activation after metformin
administration in both diet groups, maximal antitumor effects were seen in the diet-induced
obesity group suggesting that the indirect effect of metformin on circulating metabolic
hormones may play an important role as well. Genetic approaches will be necessary to
absolutely discern whether metformin exerts it effects primarily directly and/or indirectly.
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Figure 5-12
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Figure 5-12 Effect of metformin and diet on energy balance related serum hormones.
At week 26 of promotion and metformin treatment during a two-stage study, mice were
sacrificed and serum was collected via cardiac puncture from a subset of mice from each
diet/treatment group (n=7). A) Insulin B) Leptin C) Adiponectin D) Average weight of each
dietary group (including all treatments) after 30 weeks on each ad libitum fed diet. Graphs
represent the mean + SEM. (*, P<0.05, Mann-Whitney U)
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In addition, the effect of metformin on glucose tolerance was examined. Female
FVB/N mice from an ongoing two-stage skin carcinogenesis experiment from a subset of
each diet and treatment group were used for glucose tolerance tests at week 20. The DIO
group, relative to the overweight/control group, as assessed by the GTT, displayed a
modest decrease in glucose tolerance. At 20 weeks of tumor promotion, the DIO DMBATPA control group peaked at 30 minutes and averaged 387.8 + 39 mg/dl versus 340 + 30
mg/dl for the overweight/control DMBA-TPA control group. After these peaks were
achieved, blood glucose levels were consistently lower for the remainder of the time course
in the overweight/control group (Figure 5-13). However, metformin did not greatly improve
glucose tolerance in either diet group as there were not significant differences between
metformin and the DMBA-TPA control groups in either diet administered. It was surprising
that there were not significant improvements in glucose tolerance in the DIO mice, however,
these mice are not considered diabetic, and the differences between glucose tolerances in
the overweight/control versus the DIO are not all that dramatic. It should also be noted that
these readings were taken later into the tumor study at week 20 at which time the tumor
burden of mice increased as well as stress levels which could have diminished the ability to
distinguish differences in tolerance.
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Figure 5-13
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Figure 5-13 Effect of metformin and diet on glucose tolerance.
After 20 weeks of tumor promotion and metformin treatment during two-stage skin
carcinogenesis experiments, GTTs were performed on a subset of mice from each
diet/treatment group (n=10). A) Results from GTT performed on mice receiving the 10 kcal
% fat, overweight/control diet in each treatment group (DMBA-TPA control, 250 mg/kg MET
+TPA, and 50 mg/kg MET + TPA B) Results from GTT performed on mice receiving the 60
kcal % fat diet, DIO in each treatment group (DMBA-TPA control, 250 mg/kg MET +TPA,
and 50 mg/kg MET + TPA)

89

Chapter 6-Summary, Significance and Future Studies
Summary and Significance
The prevalence of obesity has drastically increased in the US over the past 30 years and is
associated with increases in various cancer risk as well as increased cancer mortality.
While DIO has consistently been shown to increase cancer risk, CR has been shown to be
an effective intervention, inhibiting carcinogenesis and increasing lifespan in a variety of
animal models. CR acts broadly and potently in chronic disease prevention and
strengthens the notion that the identification, development and study of both natural and
synthetic compounds mimicking the anticancer effects of CR should be explored. Initial
studies in this project found mTORC1 inhibitor rapamycin to be a potent inhibitor of TPAinduced skin tumor promotion. To date, this data demonstrates on a molar basis, rapamycin
to be one of the most highly potent inhibitors of skin tumor promotion by phorbol esters
(114). In addition, this inhibition by rapamycin was associated with attenuation of mTORC1
and downstream signaling in keratinocytes and inhibition of TPA-induced epidermal
hyperproliferation. Rapamycin also inhibited TPA-induced dermal inflammatory cell
infiltration as well as reduced signaling through inflammatory pathways in the epidermis.
The observed effects of rapamycin on these parameters are very similar to previous
observed effects in CR mice during two-stage skin carcinogenesis studies providing support
for rapamycin as CR mimetic agent. Furthermore, in the context of dietary energy balance,
rapamycin counteracted the effects of overweight and obese states on skin tumor
promotion and progression. Mice placed on either a 10 kcal % fat or 60 kcal % fat diet
corresponding to overweight and obese phenotypes respectively, displayed highly
significant reductions in tumor multiplicity and incidence. In this regard, tumor inhibition was
slighter more effective in the obese mice. This project has provided new insights into the
therapeutic and preventive potential of rapamycin for a range of weight phenotypes in
environmentally induced skin cancer. In addition, these studies provide the first published
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evidence for the importance of mTORC1 as a critical mediator of skin tumor promotion by
TPA, independent of Akt.
mTORC1 activity can be regulated via Akt or AMPK signaling pathways, and energy
balance has been shown to influence both pathways of activation. In addition to high serum
levels of IGF-1 and insulin and subsequent increases in cellular signaling through their
receptors to PI3K and Akt, obese states are also associated with elevations in amino acids,
glucose and ATP levels. Flux in energy metabolism can lead to activation or repression of
mTORC1 through the LKB1/AMPK pathway. Additional experiments in this project explored
the anti-cancer effects of antidiabetic drug metformin in the context of dietary energy
balance. Metformin’s primary mechanism of action is through activation of AMPK. Twostage skin carcinogenesis studies demonstrated that metformin, when administered via the
drinking water, partially blocked skin tumor promotion in both overweight and obese mice,
though it appeared to be more highly effective in the obese mice. Furthermore, this
inhibition was associated with activation of epidermal AMPK and inhibition of mTORC1.
Serum analyses also revealed metformin to decrease circulating levels of insulin and
increase adiponectin in the obese mice suggesting a dual direct/indirect mechanism of
cancer prevention in this model system. However, metformin had no effect on serum
hormone levels in the overweight mice lending to a common hypothesis that metformin may
be more effective in an obese or diabetic population. Metformin and other biguanides have
tolerable associated risks and are already widely used in the treatment of type II diabetes.
In these studies, we have provided for the first time, evidence that oral administration of
metformin in the drinking water decreases tumor development in a chemically induced
model of non-melanoma skin cancer. In addition, we have shown metformin to be slightly
more effective in obese mice due to possible dual inhibitory effects of mTORC1 inhibition as
well as reduced circulating insulin levels. There are very few studies in the literature to date
that have evaluated host metabolic status as a variable to study the anticancer effects of
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metformin. Data from this project will help fill a gap in knowledge regarding the
effectiveness of metformin in a range of weight phenotypes. These data are highly relevant
for future clinical trials as they help define target populations that will benefit most from
metformin.
Growing evidence from CR studies throughout the last few decades suggests that
the inhibitory effects of CR are multifaceted and clearly, one single pathway is not
responsible for all the anticancer effects. In addition to the IGF-1/Akt/mTOR pathway, CR
has been shown to effect components of adipokine signaling, inflammatory signaling as well
as sirtuin signaling pathways (9). Hence, combination chemoprevention strategies that
target multiple pathways are most likely to result in success at preventing cancer with
increased efficacy. While there is promise of increased efficacy with dual inhibitor
treatments, a risk of toxicity is also a concern as there is evidence of deregulation of
carbohydrate metabolism when administering PI3K, Akt, or mTOR inhibitors resulting in
hyperinsulinemia and hyperglycemia. Thus using metformin with inhibitors of the IR
pathway may prevent dose limiting toxicities. The current study demonstrated that a
combination treatment approach with a very low dose of topical rapamycin (2 nmol) and a
low dose of metformin in the drinking water resulted in an additive effect that was more
effective than either single compound alone at preventing the development of skin tumors.
Current data in the literature have not explored the effects of combination treatments with
rapamycin and metformin.
Overall, the current data support the hypothesis that elevation of mTORC1 and
subsequent activation of downstream signaling pathways is a highly important event during
skin tumor promotion and targeting this pathway alone or in combination may be an
effective chemoprevention strategy. While this project demonstrates the effectiveness of the
compounds in the context of overweight and obesity, mechanistic data obtained provides
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strong implications for chemoprevention on a broader spectrum which includes a nondiabetic, normal weight population.

Ongoing and Future Studies
Ongoing experiments in the lab are currently exploring the differential effects of an
overweight versus obese phenotype on epidermal signaling through AMPK and mTORC1
and downstream substrates after treatment with inhibitor compounds. Completing these
studies will help better elucidate the underlying mechanisms responsible for the increase in
efficacy of these inhibitors in the obese mice. In addition, we are exploring activation of
other substrates of AMPK in addition to mTORC1. Of particular interest, is AMPK’s
inhibition of de novo fatty acid synthesis and cholesterol synthesis. AMPK was initially
identified as a kinase that inhibits acetyl CoA carboxylase through phosphorylation thus
preventing the conversion of acetyl CoA to malonyl CoA subsequently inhibiting the
synthesis of fatty acids. It also phosphorylates HMG-CoA to inhibit de novo cholesterol
synthesis (147). These enzymes required for the synthesis of fatty acids and cholesterol are
highly expressed in many types of cancer (148). In addition, metformin has also been
shown in vivo to mediate some of its anticancer effects via activation of AMPK and
subsequent inhibition of ACC (100) as well as through decreased expression of FASN (99).
Because the effects of metformin in our model system on mTORC1 and p70S6K inhibition
in the epidermis are somewhat modest, it is possible that metformin may be exerting its
inhibitory effects via AMPK activation and inhibition of fatty acid synthesis or cholesterol
synthesis.
In addition, interest lies in further clarifying the effects of rapamycin downstream of
mTORC1 on the induction of autophagy in the epidermis. As presented in Chapter 5,
preliminary data gathered have presented a potential mechanism by which rapamycin
induces autophagy via mTORC1 inhibition. Future planned studies include
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immunofluorescence (IF) and immunohistochemical (IHC) staining to identify the formation
of LC3B puncta which are indicative of autophagosome formation, after rapamycin
treatment. Skin tumor samples from previous two-stage studies in each treatment group will
also be evaluated for expression of autophagic markers by western blot analysis as well as
IF and IHC.
Future work beyond the scope of this research project would likely entail delving into
pharmacokinetic/pharmacodynamic considerations of metformin use in cancer
chemoprevention and treatment. Much of the current literature as well as data from this
project suggest that some of the anticancer effects of metformin may be due to direct
mechanisms on cancer cells whereby AMPK is activated and mTORC1 is inhibited leading
to decreases in protein synthesis. Hence, there is a clear need for PK/PD studies to identify
optimal doses of metformin to be administered as well as to identify which extrahepatic
tissues will respond to treatment and to what extent. In order for metformin to be taken up
by cells, the cells have to express organic cation transporter 1 or 2 (OCT 1) (OCT 2) (149).
An interesting pharmacokinetics research question would be whether or not keratinocytes
isolated from normal epithelial tissue, papillomas, or squamous cell carcinomas express
transcripts for genes that encode organic cation transporter 1, 2, and 3. Experiments could
be carried out to confirm expression of these genes at various doses of metformin
administered via the drinking water to determine the potential for the accumulation of
metformin. Experiments could also be done to evaluate whether dietary energy balance
modulation has any effects on expression of these transporter genes. Completing these
experiments could provide valuable information on the dose of metformin that will result in
optimal response in our model system and provide further information about target
populations for which metformin should be tested in the clinic. Additionally,
pharmacodynamic experiments could be completed to evaluate the expression of
metformin’s primary target in cells, mitochondrial complex I as long as previous PK data
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from metformin ensured metformin uptake is occurring in our target cells. This research
plan would be novel, as few studies have specifically evaluated PK/PD. Understanding the
pharmacokinetics behind metformin as well as other biguanides will provide valuable
biologically based criteria for eligibility in clinical trials.
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